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A. Introduction 
This thesis is dedicated to two G protein-coupled receptors (GPCRs), namely the cannabinoid 
CB1 (A.1 – A.2) and the histamine H4 receptor (A.3). The CB1 receptor forms a part of the 
endocannabinoid system (A.2), which plays an important role in the brain and is activated by  
Δ9-tetrahydrocannabinol (Δ9-THC; A.1), one of the major constituents of hashish and marijuana. 
The H4 receptor (A.3) mainly occurs in immune cells; whether it plays a role also in the brain is 
matter of debate. 
 
1. Δ9-THC 
The main psychoactive ingredient of the Cannabis sativa plant is Δ9-THC (for chemical structure 
see Table 2). Even though the cannabis plant and its effects have been known and used 
recreationally or curatively since ancient times, the compound responsible for its psychoactive 
effects, Δ9-THC, remained undiscovered till the early 1960s (Greydanus et al. 2013). The other 
components of the endocannabinoid system were discovered two decades later and even to this 
day, the endocannabinoid system is not completely understood (Mechoulam and Parker 2013). 
The properties of cannabis and Δ9-THC, including their therapeutic potential and negative 
effects, were described in hundreds of papers. 
Briefly, the use of marijuana (Cannabis sativa plant preparation) by humans and in laboratory 
animals impairs cognition and working memory, causes euphoria or sedation, sleepiness, 
dizziness, mood alterations, tachycardia and immune modulation; its analgesic, anti-emetic, 
appetite-stimulant and muscle relaxant effects were considered as therapeutic actions  
(Hollister 1986). Due to its antispastic and analgesic activity Δ9-THC is used therapeutically in 
several countries under the trade name Sativex (international non-proprietary name: 
nabiximols; an oromucosal spray consisting of Δ9-THC and cannabidiol) against neuropathic 
pain and spasticity in Multiple Sclerosis patients (Vermersch 2011; Robson 2014). The use of  
Δ9-THC or its synthetic derivative nabilone was reported to be effective in the clinic against 
nausea and vomiting, especially when associated with chemotherapy. Other possible 
applications of “medicinal marijuana” are still discussed (Di Marzo and Petrocellis 2006; 
Grotenhermen and Müller-Vahl 2012; Greydanus et al. 2013; Robson 2014). 
The common therapeutic use of marijuana is hindered by many facts such as its adverse effects 
which, especially in adolescent, chronic users, include an increased risk to develop a mental 
illness or cognitive disorder (Di Forti et al. 2007; Boyce and McArdle 2008; Rubino et al. 2012; 
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Renard et al. 2014; Lubman et al. 2015), its addictive potential (Hall and Degenhardt 2013), its 
possible role as a “gateway drug” (Volkow et al. 2014) and the fact that marijuana is the most 
commonly used illicit drug in the world mainly in young people (Greydanus et al. 2013;  
Renard et al. 2014). Hence, cannabis and its preparations are subject to the Single Convention on 
Narcotic Drugs and are listed in the Yellow List, a strict international regulatory agreement to 
prohibit and control drugs of abuse (INCB 2013). Nevertheless, the investigation of the effects of 
Δ9-THC was a driving force for the development of indirect ways to activate the 
endocannabinoid system. 
 
1.1 Δ9-THC tolerance development 
The abuse potential of Δ9-THC observed in humans and confirmed in animals is one of the major 
issues speaking against the therapeutic use of cannabinoids (Ramesh et al. 2011;  
Volkow et al. 2014). Tolerance development after long-term Δ9-THC treatment is known to occur 
in humans and was investigated in detail in animal studies in terms of brain region, dose and 
time-course (Zhuang et al. 1998; Bass and Martin 2000; McKinney et al. 2008). The mechanism 
of cannabinoid tolerance which is CB1 receptor-dependent (Martin et al. 2004) still needs to be 
better understood; however, several signalling pathways and biological processes involved in 
tolerance development are already known. Chronic exposure of GPCRs to an agonist can result in 
several receptor adaptations: GPCR desensitization which occurs as a consequence of receptor 
phosphorylation resulting in uncoupling of G protein and receptor. Further adaptive processes 
comprise receptor down-regulation (decrease of receptor number) with receptor degradation 
(Tsao and von Zastrow 2000) and sequestration of the receptor from the cell surface, a 
mechanism termed internalization (Ferguson and Caron 1998; Roth et al. 1998). All these 
mechanisms may occur depending on the brain region and treatment model, hence, the regional 
differences of receptor changes may explain different behavioural responses to cannabinoids of 
laboratory animals (Martin et al. 2004; González et al. 2005). As described in section B.2.3.1 
below, the 35S-GTPγS binding assay directly measures the G protein response to receptor 
activation, which makes it an optimal method to measure receptor desensitization after chronic 
cannabinoid treatment. 
 
1.2 Does aging influence Δ9-THC tolerance development? 
The age of the subject exposed to Δ9-THC is an essential factor which influences the acute  
Δ9-THC effects as well as tolerance phenomena both in humans and animals (for research 
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reports see Cha et al. 2006; Schramm-Sapyta et al. 2007; Swartzwelder et al. 2012; for reviews 
see: González et al. 2005; Rubino and Parolaro 2008; Realini et al. 2009; Renard et al. 2014; 
Lubman et al. 2014). Adolescence in humans (the lifetime period from 12 to 17 years)  
is characterized by strong neurobehavioural plasticity and represents a critical period for brain 
development. Numerous maturation processes in the central nervous system take place,  
e.g. neuronal maturation, synaptic pruning, myelination, volumetric growth and changes in 
receptor distribution; many of these processes are influenced by the endocannabinoid system 
(Renard et al. 2014). Therefore, particularly during this period of dynamic neurological changes 
intensified activation of the cannabinoid system e.g. through cannabinoid consumption, can lead 
to alterations in the brain and long-lasting consequences (Renard et al. 2014; Lubman et al. 
2015). 
Further examples of differential responses of the endocannabinoid system depending on age 
were provided by experiments on animals. As shown by Cha et al. (2006), adult rats chronically 
treated with Δ9-THC and tested for spatial and non-spatial learning in the water maze, 
performed better than adolescent animals treated in the same manner. Accordingly Schramm-
Sapyta et al. (2007) from the same laboratory argue that this difference is related to the strong 
addictive potential of Δ9-THC at a young age. Anxiety and aversion, known as undesirable effects 
of marijuana (and acute Δ9-THC treatment), were decreased in behavioural tests in adolescent 
rats whereas the inhibitory effect of Δ9-THC on locomotion was stronger in adult than in 
adolescent animals. Further analysis regarding the differential effects of Δ9-THC treatment in 
adolescent and adult rats in behavioural tests and receptor level measurement was provided by 
Moore et al. (2010). In this research report, the functional coupling of CB1 receptors to Gαi/o 
protein was lower in adult than in adolescent rats after chronic Δ9-THC treatment although CB1 
receptor number and distribution did not differ. In harmony with these data, 35S-GTPγS binding 
activated by the cannabinoid CB1 receptor agonist WIN 55,212-2 indicated lower receptor 
desensitization in adolescent than in adult animals. 
This thesis focuses on Δ9-THC tolerance development in adolescent and aged mice using 
behavioural and 35S-GTPγS receptor-binding experiments and provides further evidence for  
age-dependent differential responses of the endocannabinoid system. 
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2. Endocannabinoid system 
2.1 Introduction to the endocannabinoid system 
Components of the endocannabinoid system 
The endocannabinoid system is a dynamic complex of cannabinoid receptors, their endogenous 
lipid ligands and the enzymes involved in production and degradation of these ligands (Battista 
et al. 2012) as schematically presented in Figure 1. The two cannabinoid receptors, CB1 and CB2, 
belong to the G protein-coupled receptor superfamily and interact with endogenous ligands. 
These ligands are lipophilic substances of which anandamide and 2 AG are the best 
characterized ones (Mechoulam et al. 1998). The dynamic character and homeostasis of the 
endocannabinoid system is provided by the enzymes involved in the biosynthesis (Wang and 
Ueda 2009) and degradation (Basavarajappa 2007; Chanda et al. 2010) of the endogenous 
ligands. 
 
Figure 1. The main components of the endocannabinoid system. The same background colour (green and blue) has 
been used for the lipid ligands and the respective enzymes involved in their synthesis and degradation.  
2-AG – 2-arachidonoylglycerol, AEA - anandamide, DAGL – diacylglycerol lipase, FAAH – fatty acid amide hydrolase, 
GPCRs – G protein-coupled receptors, MAGL – monoacylglycerol lipase, NAPE-PLD –  
N-acylphosphatidylethanolamine-hydrolysing phospholipase D, NAT – N-acetyltransferase, PLC – phospholipase C. 
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2.1.1 Cannabinoid receptors 
Cannabinoid receptor types 
The two cannabinoid receptors CB1 and CB2 were characterized in detail over the past decades. 
The CB1 receptor cloned by Matsuda et al. (1990) and the CB2 receptor cloned by Munro et al. 
(1993) exhibit 48 % of genetic homology. Both receptors are coupled to Gi/o protein, thereby 
inhibiting the conversion of ATP to cAMP by adenylyl cyclases and activating mitogen-activated 
protein kinase (MAPK) pathways. The CB1 receptor also influences some types of potassium and 
calcium channels (as shown in Figure 2; for review see: Howlett et al. 2002). The resemblance of 
the cannabinoid receptor type 1 and 2 results in responses with similar potency to exogenous 
ligands, such as Δ9-THC, WIN 55,212-2, CP 55 940 or the endogenous agonists anandamide 
(AEA) and 2-AG (see Felder et al. 1995; for structures see Table 2). In addition to the differences 
in amino acid sequence, the CB1 and CB2 receptors have different tissue distributions and 
different signalling mechanisms. While CB1 receptors are expressed presynaptically at terminals 
of the central and peripheral nervous system causing inhibition of neurotransmitter release 
(Schlicker and Kathmann 2001; Szabo and Schlicker 2005), the CB2 receptors are located mainly 
on the cells of the hematopoietic system and modulate the immune response by modulation of 
cytokine release and migration of immune cells (Malfitano et al. 2014). Although the CB1 
receptor is one of the most widely expressed GPCRs in the CNS (Herkenham et al. 1990), its 
expression in non-neuronal tissues, such as spleen, was also described (Howlett et al. 2002). On 
the other hand, contradictory results were published regarding the expression of the CB2 
receptor in the CNS and this issue remains controversial (Gong et al. 2006; Ashton et al. 2006; 
Atwood and Mackie 2010; Onaivi 2011; Onaivi et al. 2012; Baek et al. 2013). Due to its 
expression in the immune system, the CB2 receptor is investigated as a potential target for the 
treatment of inflammatory diseases and pain (Klein 2005). 
There may be further, non-CB1/CB2 cannabinoid receptors. The orphan G protein-coupled 
receptor GPR55 was discovered in human striatum and other brain regions by Sawzdargo et al. 
(1999) and later classified as a novel cannabinoid receptor (Ryberg et al. 2007) based on its  
35S-GTPγS binding activation by the cannabinoids. On the other hand, the fact that GPR55 is not 
activated by the potent cannabinoid agonist WIN 55,212-2 (Ryberg et al. 2007) casts some doubt 
on its classification as a cannabinoid receptor. The distribution and physiology of GPR55 
remains to be further investigated. 
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Cannabinoid receptor agonists 
The agonists of the cannabinoid receptors (for chemical structures see Table 2) are commonly 
classified in four main groups according to their chemical structures (Childers and Breivogel 
1998) as listed in Table 1. 
 
Group Chemical structure Representative 
compound(s) 
Origin 
I – Classical cannabinoids dibenzopyran  Δ9-THC plant-derived 
II – Non-classical 
cannabinoids 
bi- and tri-cycle analogs of 
Δ9-THC, without pyran ring 
CP 55,940 synthetic 
III – Aminoalkylindoles aminoalkylindoles WIN 55,212-2 synthetic 
IV– Eicosanoid group 
       (endocannabinoids) 
derivatives of arachidonic 
acid 
2-AG, AEA endogenous 
Table 1. Classification of the cannabinoid receptor ligands (agonists) based on their chemical structure (Childers and 
Breivogel 1998). For chemical structures of the five compounds, see Table 2.  
 
The representative cannabinoid receptor agonist is Δ9-THC, a partial agonist at both cannabinoid 
receptors (Pertwee et al. 2010). It belongs to the classical cannabinoid group and is the main 
psychoactive component of marijuana (Cannabis sativa). Since Δ9-THC was used in the 
experimental part of this thesis, a separate part of the introduction (see section A.1) was 
dedicated to Δ9-THC and its activity, its medical and non-medical applications and risks. 
The non-classical cannabinoid CP 55,940 and WIN 55,212-2, the representative of the group III, 
act as potent (but not selective) cannabinoid receptor agonists and are not clinically used as 
opposed to the active components of marijuana (Δ9-THC or cannabidiol). Nevertheless, many of 
the synthetic cannabinoids have implications in experimental pharmacology. CP 55,940 and  
WIN 55,212-2 are widely used in animal models both in vitro and in vivo because of their affinity 
to CB1 and CB2 receptors in the low nanomolar range and their relatively high efficacy at both 
receptor types (Pertwee and Ross 2002). These synthetic ligands, as well as Δ9-THC, produce 
characteristic, behavioural effects in animals, including the so-called tetrad test for cannabinoid 
activity. The tetrad includes hypothermia, analgesia, hypoactivity, and catalepsy (reviewed by 
Chaperon and Thiébot 1999). 
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The fourth class of cannabinoids, the eicosanoid group, consists of arachidonic acid derivatives 
which are endogenous, highly lipophilic substances. The most investigated ones are AEA and  
2-AG (Mechoulam et al. 1998). AEA (anandamide) was primarily found in brain tissue and later 
also in other organs. It is a partial agonist of the CB1 receptor and a partial agonist with very low 
intrinsic activity of the CB2 receptor (Pertwee et al. 2010). AEA administered i.p. to rodents 
mimics the effects caused by Δ9-THC administration (Fride and Mechoulam 1993). The second 
endocannabinoid, 2-AG (2-arachidonoylglycerol), was found in numerous tissues in significantly 
higher concentrations than AEA, with the highest concentration in the nervous system  
(Sugiura et al. 2002). It is a full agonist at both types of cannabinoid receptors with a slightly 
lower affinity to the CB2 receptor (Pertwee et al. 2010). The biosynthesis and degradation of AEA 
and 2-AG, the key processes, that maintain the integrity of the endocannabinoid system, are 
discussed in the following sections. 
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Origin Structure MW [g/mol] Function 
Plant origin, 
exogenous 
 
314.47 Non-
selective 
CB1 and CB2 
partial 
agonist 
Synthetic, 
exogenous 
 
376.57 Non-
selective 
CB1 and CB2 
full agonist 
 
522.61 Non-
selective 
CB1 and CB2 
full agonist 
Endogenous  
347.53 Non-
selective 
CB1 and CB2 
partial 
agonist 
 
378.6 Non-
selective 
CB1 and CB2 
full agonist 
Table 2. Chemical structures, molecular weights and receptor interactions of five representative cannabinoid receptor 
agonists. 
 
2.1.2 Enzymes involved in endocannabinoid synthesis and degradation  
The optimal balance within the endocannabinoid system is provided by the enzymes involved in 
biosynthesis and degradation of the endocannabinoids. Figure 2 presents the main pathways of 
endocannabinoid metabolism in neuron. Although anandamide and 2-AG share numerous 
chemical and physiological properties and activate the same receptors, the biosynthesis and 
degradation of these lipid molecules is controlled by different enzymatic pathways, as described 
below in detail. 
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Figure 2. Mechanisms involved in retrograde signalling in neurons and CB1 receptor functions. CB1 receptor activation 
caused by the endocannabinoids AEA and 2-AG inhibits cAMP production by AC, regulates channels for K+ and Ca2+ 
ions, inhibits neurotransmitter release to the synaptic cleft and activates MAPK (Howlett 2002). The concentration  
of AEA and 2-AG is controlled by “on demand” synthesis and degradation. The synthesis of AEA and 2-AG takes  
place in the postsynaptic neuron. Endocannabinoids are transported through the neuronal membrane  
and activate CB1 receptors. The enzymes PLC and DAGL are involved in the synthesis of 2-AG whereas NAT  
and NAPE-PLD take part in the AEA production. FAAH (postsynaptic) and MAGL (presynaptic) hydrolyse AEA  
and 2-AG, respectively (Blankman et al. 2007). The FAAH inhibitor PF-3848 blocks the degradation of AEA  
and increases its concentration (Ahn et al. 2009) whereas JZL 184 is a potent and selective MAGL  
inhibitor which increases 2-AG levels (Long et al. 2009a; 2009b). 2-AG – 2-arachidonoylglycerol, AA – arachidonic 
acid, AC – adenylyl cyclase, AEA – anandamide, ATP – adenosine triphosphate, cAMP – cyclic adenosine 
monophosphate, DAG - diacylglycerol, DAGL – diacylglycerol lipase, FAAH – fatty acid amide hydrolase,  
MAGL – monoacylglycerol lipase, MAPK – mitogen-activated protein kinase, NAPE - N-acylphosphatidylethanolamine, 
NAPE-PLD – N-acylphosphatidylethanolamine hydrolysing phospholipase D, NAT – N-acetyltransferase,  
PE – phosphatidylethanolamine, PI - phosphatidylinositol, PLC – phospholipase C. Figure adapted and modified from 
Ahn et al. (2008). 
 
  
Introduction 
10 
Endocannabinoid synthesis – process “on demand”  
Endocannabinoids are synthesized from membrane phospholipids at the moment of their 
intended action (“on demand”), contrary to neurotransmitters or neuropeptides which are 
stored in cell vesicles (Piomelli 2003; Ahn et al. 2008; Wang and Ueda 2009). More recent 
studies reported that endocannabinoids, mainly AEA, can be also stored in the lipid droplets in 
the cells (reviewed and discussed by Maccarrone et al. 2010; Min et al. 2010; Fezza et al. 2014), 
however, this hypothesis awaits further investigation. 
As shown in Figure 3, the pathway of AEA formation (the so-called “transacylation-
phosphodiesterase pathway”) consists of two major steps. The enzymes involved in this process 
are N-acyltransferase (NAT) and N-acylphosphatidylethanolamine-hydrolysing phospholipase D 
(NAPE-PLD). In the first step, NAT catalyses the reaction of phosphatidylethanolamine (PE) with 
1-arachidonoyl-phosphatidylcholine (PC); by this reaction N-arachidonoyl-PE (and lyso PC as 
by-product) are formed. In the second step, NAPE-PLD hydrolyses N-arachidonoyl-PE to AEA 
and phosphatidic acid (PA). Alternative routes of anandamide biosynthesis e.g. studied on  
NAPE-PLD knockout mice (NAPE-PLD-/-), were also reported (for review see: Wang and Ueda 
2009 and Ahn et al. 2008). 
 
Figure 3. Biosynthesis of anandamide (AEA), “the transacylation-phosphodiesterase pathway”. AEA is formed in two 
steps catalyzed by NAT and NAPE-PLD. NAPE-PLD – N-acylphosphatidylethanolamine-hydrolysing phospholipase D; 
NAT – N-acyltransferase; PA – phosphatidic acid; PC – phosphatidylcholine; PE- phosphatidylethanolamine.  
Modified from Wang and Ueda (2009). 
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The biosynthesis of 2-AG is presented in Figure 4. This process is mediated by the membrane 
enzymes phospholipase C (PLC) and diacylglycerol lipase (DAGL). PLC catalyses hydrolysis of 
phosphatidylinositol (PI) to give diacylglycerol (DAG) and inositol 1-phosphate. In the second 
step 2-AG and fatty acid are formed by DAGL (Ahn et al. 2008; Wang and Ueda 2009). The 
research on DAGL deficient mice provided evidence that DAGL activity and the 2-AG molecule 
are essential for retrograde signalling at synapses (Gao et al. 2010; Tanimura et al. 2010). 
Alternative biosynthesis pathways of 2-AG may also occur and are not described in detail (for 
reviews see Sugiura et al. 2006 and Murataeva et al. 2014). 
 
Figure 4. Biosynthesis of 2-arachidonoylglycerol (2-AG). In a two-step reaction catalyzed by the lipases PLC and DAGL, 
2-AG is formed. PI – phosphatidylinositol; PLC- phospholipase C; DAGL – diacylglycerol lipase. Modified from Wang 
and Ueda (2009). 
 
Endocannabinoid degradation 
As illustrated in Figure 2, after biosynthesis in the postsynaptic neurons, endocannabinoids are 
released to the synaptic cleft and migrate to cannabinoid receptors. Complex processes are 
involved in the endocannabinoid transport mechanism (Ehehalt et al. 2006; Ahn et al. 2008). 
The cannabinoid receptors activated by the endocannabinoids trigger the signalling cascade and 
regulate ion channels and neurotransmitter release. After cellular uptake, two endocannabinoid-
degrading enzymes, namely the postsynaptically located fatty acid amide hydrolase (FAAH) and 
the presynaptically located monoacylglycerol lipase (MAGL) hydrolyse anandamide and 2-AG, 
respectively, and terminate the retrograde signalling of the endocannabinoids (Piomelli 2003; 
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Ahn et al. 2008). The enzymes FAAH and MAGL play a crucial role as regulators of the 
endocannabinoid levels in the tissues. 
The main enzyme involved in the degradation of anandamide is FAAH (recently re-named  
FAAH-1). Another two degrading enzymes with minor importance for the tissue levels of AEA, 
namely NAAA (reviewed by Ueda et al. 2010) and an isoform of FAAH-1 termed FAAH-2  
(Cravatt et al. 2001) were described as well. The scheme of AEA degradation is presented in 
Figure 5. The major metabolic pathway involves FAAH-1 activity in which AEA is hydrolysed and 
arachidonic acid and ethanolamine are the degradation products. NAAA hydrolyses AEA to the 
same degradation products, however, its role is still poorly understood (Ueda et al. 2010). 
 
Figure 5. Degradation of anandamide by FAAH and/or NAAA. FAAH – fatty acid amide hydrolase;  
NAAA – N-acylethanolamine-hydrolysing acid amidase. Modified from Wang and Ueda (2009). 
 
The chemical structures of AEA and 2-AG are similar and this led to the hypothesis that these 
two endocannabinoids could share the same enzyme during degradation. The involvement of 
FAAH in 2-AG hydrolysis in vitro was reported by Goparaju et al. (1998). Further investigation 
showed that 2-AG is not degraded by FAAH enzyme in vivo (Lichtman et al. 2002). Goparaju et al. 
(1999) investigated the potential involvement of MAGL in 2-AG degradation; the role of MAGL in 
2-AG hydrolysis in the brain was reported by Dinh et al. (2002). The same authors described 
high levels of MAGL in the CNS and found decreased 2-AG levels in MAGL-overexpressing 
neuronal cells. MAGL inhibitors such as URB602 provide further evidence about the role of 
MAGL in the degradation process of 2-AG (Makara et al. 2005). Subsequently, JZL 184 (for 
chemical structure see Table 3) was reported as a potent and highly selective  
MAGL inhibitor (Long et al. 2009b) and finally, the development of the MAGL knockout mouse 
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(MAGL-/-) confirmed the substantial role of MAGL in the regulation of the 2-AG levels (Chanda et 
al. 2010). Although further enzymes involved in 2-AG degradation were discovered (Blankman 
et al. 2007), the major role of MAGL is beyond any doubt (Murataeva et al. 2014). 
The degradation of 2-AG by MAGL is presented in Figure 6. MAGL hydrolyses 2-AG to 
arachidonic acid and glycerol. 
 
Figure 6. Degradation of 2-AG by MAGL (monoacylglycerol lipase). Modified from Wang and Ueda (2009). 
 
Type Structure MW [g/mol] Function 
Synthetic 
 
520.49 
 
Non-competitive 
irreversible 
MAGL inhibitor 
Table 3. Chemical structure and molecular weight of the MAGL inhibitor JZL 184. 
 
The indirect activation of the endocannabinoid system - a potential therapeutic target 
The use of Δ9-THC as a therapeutic agent was discussed in section A.1. Targeting the receptor 
through its ligand seems to be the most direct and simple strategy in a search for  
new therapeutic agents. Nevertheless, the discovery of highly selective and potent inhibitors of 
the endocannabinoid degrading enzymes, such as PF-3845 for FAAH (Ahn et al. 2009; 
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Tchantchou et al. 2014) and JZL 184 for MAGL (Long et al. 2009a; 2009b), opened new horizons 
for the endocannabinoid system as a therapeutic target. 
Since one of the subjects of this thesis is the effect of different doses of JZL 184 on 
endocannabinoid levels and CB1 receptor adaptation in mouse hippocampus, the rest of this 
section will describe the effects of MAGL (but not of FAAH) inhibitors. 
JZL 184 was developed in Cravatt’s laboratory by Long et al. (2009a) using activity-based 
proteomic methods (for the chemical structure of JZL 184, see Table 3). The properties of  
JZL 184, such as its (i) high potency (causing significant elevation of 2-AG concentrations also in 
vivo), (ii) selectivity (no effect on AEA concentration), (iii) rapid and sustained action (elevation 
of 2-AG levels over at least 8 h) and (iiii) ability to evoke CB1-dependent behavioural effects (as 
reported by Long et al. 2009a), made this compound a breakthrough in the research on MAGL 
and its role in the 2-AG mediated signalling.  
MAGL may have a therapeutic potential for a number of diseases and disorders (Fowler 2012; 
Mulvihill and Nomura 2013; Pertwee 2014). Considering the regulatory functions  
of the endocannabinoid system on pain sensation, inflammation, memory and appetite  
(Di Marzo 2009), an increased 2-AG concentration through MAGL blockade may be useful for the 
treatment of pain and inflammation (Kinsey et al. 2009; 2010; Ghosh et al. 2013; Ulugöl 2014), 
neurodegenerative diseases (Centonze et al. 2007; Chen et al. 2012; Bilkei-Gorzo 2012;  
Aso and Ferrer 2014), anxiety-related disorders (Sciolino et al. 2011) or obesity and metabolic 
disorders (Silvestri and Di Marzo 2013; D’Addario et al. 2014). Moreover, MAGL blockade was 
shown to slow cancer cell migration, invasiveness and tumorigenicity in several cancer types 
(Mulvihill and Nomura 2013). 
Although JZL 184 administration to mice induces endocannabinoid-mediated behavioural effects 
in the tetrad test for cannabinoid activity (analgesia, hypomotility, hypothermia and catalepsy; 
Chaperon and Thiébot 1999; Wiley and Martin 2003), the effects of long-term administration of 
JZL 184 were surprisingly different from those due to acute/single administration. The  
MAGL-deficient mouse (MAGL-/-; Chanda et al. 2010) with permanent elevation of 2-AG levels 
did not show dramatic changes of the behaviour without treatment although the behavioural 
response after WIN 55,212-2 treatment was decreased. The density and agonist-mediated 
signalling of the CB1 receptors were reduced in MAGL knockout mice, however, no changes in 
CB1 receptor mRNA levels were found (Chanda et al. 2010). A further question in this context 
was, whether the effects of the long-term pharmacological blockade of MAGL activity in mice are 
comparable with the profile of MAGL-/- mice. Schlosburg et al. (2010) showed a functional 
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antagonism of the endocannabinoid system occurring after chronic JZL 184 treatment  
(40 mg/kg JZL 184, i.p. administration for 6 days). The mice exhibited tolerance to the CB1 
agonist-mediated effects in the behavioural pain assay. The in vivo experiments were confirmed 
by in vitro studies in which CB1 receptor desensitization was observed, among others in 
radioligand [3H]-SR141716A binding and in cannabinoid receptor-activated 35S-GTPγS receptor 
binding and 35S-GTPγS binding autoradiography. 
Surprisingly, further experiments in MAGL-/- mice showed, that contrary to the administration of 
synthetic cannabinoid receptor agonists which cause deficits in memory, attention and cognition 
in human and in animals (Hall and Degenhardt 2009; Zanettini et al. 2011; Skosnik et al. 2012; 
Mechoulam and Parker 2013), the permanent increase in 2-AG occurring in MAGL-/- mice was 
associated with an improved performance in learning and cognition in behavioural tests (Pan et 
al. 2011). Additionally, the hippocampal long term potentiation (LTP) of synaptic transmission, 
supposed to be a cellular model of learning and memory (Bliss and Collingridge 1993), was 
enhanced in MAGL-/- mice, whereas synthetic cannabinoids caused suppression of the LTP in the 
hippocampus in vitro (Hoffman et al. 2007) and in vivo (Hill et al. 2004). The discrepancies point 
to a complex, dual nature of the endocannabinoid system (Sarne et al. 2011), which leaves an 
urgent need for further research to fully understand the character of this system. 
In several diseases, up-regulation of the endocannabinoid system serves as an autoprotective 
mechanism which reduces unwanted pathological effects or even slows the disease progression 
(Pertwee 2014). Several pieces of evidence for the neuroprotective character of the 
endocannabinoids make indirect strategies of endocannabinoid system activation a promising 
target for the treatment of a number of diseases and disorders (Parolaro et al. 2010; Pertwee 
2014). In this thesis, I investigated the influence of various doses of JZL 184 on endocannabinoid 
levels and CB1 receptor function as determined in 35S-GTPγS binding experiments. 
 
2.2 Alterations of the endocannabinoid system with age 
The involvement of the endocannabinoid system in aging was investigated among others by 
Bilkei-Gorzo and co-workers (reviewed by Bilkei-Gorzo 2012). They found that the lack of the 
CB1 receptor is associated with an early onset of cognitive/learning impairment and neuronal 
loss and that the CB1 receptors on GABAergic neurons protect against age-related neuronal 
degenerative changes and inflammation (Bilkei-Gorzo et al. 2005; Albayram et al. 2011; 
Albayram et al. 2012). Since the endocannabinoid system plays a neuroprotective role and most 
of the neurodegenerative diseases are related to old-age, targeting of this system could provide 
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new strategies in the prevention and treatment of neurodegenerative diseases (Marchalant et al. 
2012; Sánchez and García-Merino 2012). 
On the other hand, not only in the aging brain, but also in the developing adolescent brain, the 
endocannabinoid system plays a crucial role during dynamic neuronal changes and processes 
associated with adolescent behaviour and cognitive functions (Trezza et al. 2008; Mechoulam 
and Parker 2013). The proper functioning of the endocannabinoid system is necessary for 
mental health in the adulthood (Realini et al. 2009; Renard et al. 2014; Lubman et al. 2015). The 
differential response to the cannabinoid Δ9-THC in adolescent when compared to adult animals 
(as described in section A.1.2) provides further confirmation of the fact that endocannabinoid 
system activity changes during ontogeny and aging. 
As reviewed by Spear (2000) and Andersen (2003), there is a fundamental strategy in the 
development of the brain in mammals termed “functional validation”. The functional validation 
is based on synapses and receptor overproduction and elimination and consists of two major 
phases, linked with two lifetime periods. The first phase, occurring just before birth after 
completion of the brain innervation, is characterised by the programmed cell death (cell 
apoptosis) of 50% of the neurons. At this point dramatic changes of the brain morphology take 
place and synaptic transmission efficiency is improved. The second phase is related to the 
periadolescent period and characterized by an immense overproduction of synapses and 
receptors, which are subsequently pruned or eliminated. The endocannabinoid system, which 
appears already in early prenatal stages in rats and in humans (for review see: Harkany et al. 
2007), undergoes developmental changes different from those of the functional validation. 
Contrary to most of the neuroreceptor systems associated with functional validation, the central 
cannabinoid receptor (CB1) density increases during the maturation from childhood through 
adolescence to adulthood to reach constant levels as reported by Belue et al. (1995). This 
mechanism of ontogeny was later confirmed by Verdurand et al. (2011) using the emission 
positron tomography in a study in adolescent and adult rats. 
The dopamine receptor families D1 and D2 represent another example of the lack of functional 
validation in the development of central nervous system receptors. Expression of  
dopamine receptors increases until puberty; subsequently they are pruned to the adult level 
(Leslie et al. 1991; Teicher et al. 1995). Another transmitter of the central nervous system, the 
function of which changes during development/maturation, is γ-aminobutyric acid (GABA). 
Rivera et al. (1999) proved that GABA, known as an inhibitory neurotransmitter in adolescents 
and adults, acts excitatory in early developmental phases and switches from excitatory to 
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inhibitory activity during ontogenetic brain development. The alterations of some selected 
mechanisms during ontogeny in the CNS of rats are shown in Figure 7. 
 
Figure 7. Comparison of the age periods and ontogeny events in rats. Adapted and extended from Spear (2000), 
Andersen (2003) and Verdurand et al. (2011). FV – functional validation. 
1Belue et al. (1995); 2Rodríguez de Fonseca et al. (1993); 3Andersen (2003); 4Rivera et al. (1999) 
 
With respect to the endocannabinoid system, Trezza et al. (2008) and Lubman et al. (2014) 
reported strong behavioural consequences to cannabinoid exposure during the adolescence of 
humans and animals. However, in humans, research is restricted due to ethical reasons and 
several experimental limitations, such as limited participant number, heterogeneity of  
the groups, limited behavioural and in vitro methods affect the comparability and 
reproducibility of results. Despite these difficulties, numerous studies confirm the negative 
effects of adolescent cannabis use in humans (Rubino and Parolaro 2008; Realini et al. 2009; 
Rubino et al. 2009; 2012; Renard et al. 2014; Lubman et al. 2014). For instance, the review of 
Trezza et al. (2008) stated that the marijuana use in adolescence results in increased incidence 
of psychotic disorders (increased risk of the early schizophrenia onset or depression; Bossong 
and Niesink 2010) and impaired cognitive behaviour and memory. Lubman et al. (2014) 
identified synaptic pruning and white matter development as two crucial processes that may be 
impaired by cannabis consumption in adolescence. However, the mechanisms underlying the 
adolescence as a period of particularly high risk have still to be better understood. The latter 
problems, further risks, such as abuse and addictive potential of cannabinoids and their 
numerous adverse effects hinder their broader therapeutic use (Hall and Degenhardt 2009; 
Volkow et al. 2014; Filbey et al. 2014).  
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3. Other GPCRs –  histamine H4 receptor 
Histamine is a biogenic amine involved in numerous physiological and pathological processes in 
mammalian organisms. The regulation of gastric secretion, inflammatory processes and 
pathological allergic responses are associated with histamine. Moreover, histamine acts as a 
neurotransmitter in the CNS (Schwartz 1975). At present, four histamine receptor subtypes, H1, 
H2, H3 and H4, are known (Haaksma et al. 1990; Leurs et al. 1995; Parsons and Ganellin 2006). All 
these receptors belong to the G protein-coupled receptor superfamily (Alexander et al. 2013). H1 
receptor antagonists are known as antiallergic drugs. H1 receptor antagonists of the first 
generation and single antagonists of the second generation possess strong sedative effects which 
point to the presence of H1 receptors in the brain (Parsons and Ganellin 2006; Simons and 
Simons 2011). Besides histamine H1 also H2 and H3 receptors are found in the brain (Arrang et al. 
1983; Haas et al. 2008). Although no histamine H3 receptor ligands have been introduced to the 
market yet, the H3 inverse agonist pitolisant is currently in an advanced stage of clinical trials as 
a potential medicine against neurological disorders like narcolepsy or epilepsy (Gemkow et al. 
2009; Schwartz 2011; Kasteleijn-Nolst Trenité et al. 2013; Dauvilliers et al. 2013). 
The H4 receptor is the most recent addition to the histamine receptors. It is mainly expressed in 
hematopoietic cells and plays a role in immune response and inflammatory processes (Zhang et 
al. 2006; Walter et al. 2011). Although the expression of the histamine receptor subtypes H1, H2 
and H3 the brain is well defined (Arrang et al. 1983; Timm et al. 1998; Haas et al. 2008; Gemkow 
et al. 2009), the presence of the histamine H4 receptor in the CNS is controversial as discussed by 
Schneider et al. (2015). Although H4 receptor expression on the mRNA level was not found in the 
brain in the early study by Liu et al. (2001), it was detected later on by Strakhova et al. (2009). 
Moreover, research reports claiming the functional expression of the H4 in the brain of mouse 
(Connelly et al. 2009) or rat (Desmadryl et al. 2012) were published (and reviewed by Marson 
2011). In some studies, Western blots have been used to show the occurrence of H4 receptor 
pattern in the brain; there is, however, much doubt whether really H4 receptors were detected 
since the antibody used in those studies does not fulfil the strict specificity criteria (critically 
discussed by Schneider et al. 2015). 
Since, H4 receptor mRNA expression in human and mouse cerebral cortex tissue was detected 
using RT-PCR in Prof. Schlicker’s laboratory (Schulte 2011), research on the H4 receptor has 
been continued in this thesis. So an attempt has been made to detect H4 receptor mRNA also in 
guinea pig cerebral tissue. Furthermore, I studied whether a functional readout of H4 receptors 
in the brain can be identified, using the 35S-GTPγS binding method. 
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4. Aim of this thesis 
This thesis focuses on the 35S-GTPγS binding assay combined with other experimental methods 
to investigate two G protein-coupled receptors. I examined whether adaptive changes of 
cannabinoid CB1 receptors occur following their direct and indirect activation through 
appropriate drugs and whether functional histamine H4 receptors occur in the brain. 
The aim of the main part of this thesis related to the endocannabinoid system was: (i) to 
establish experimental conditions, including a selective agonist and appropriate groups, which 
were then used in the experimental series. Subsequently, (ii) in mice pre-treated chronically 
with Δ9-THC, tolerance development to a challenge dose of Δ9-THC was examined using a 
behavioural paradigm (Open Field Test), followed by agonist-stimulated 35S-GTPγS binding 
studies. The functional changes in CB1 receptor activity caused by chronic Δ9-THC treatment 
were compared in adolescent and aged mice. 
Furthermore, (iii) JZL 184, a selective MAGL inhibitor, was applied to mice in different doses and 
for different time periods to investigate an impact of these factors on the endocannabinoid levels 
in the brain (hippocampus). The endocannabinoids were detected and their concentration was 
measured using the LC-MS/MS (LC-MRM) method. The influence of the tested regimens on CB1 
receptor activity was measured in 35S-GTPγS binding studies. The relationship between JZL 184 
treatment regimen, endocannabinoid concentrations and CB1 receptor activity in mouse 
hippocampus was analyzed. The goal of this part was to find a treatment schedule with JZL 184 
which enhances endocannabinoid concentration in the brain without down-regulation of the CB1 
receptors. 
Finally, I studied whether a functional H4 receptor based on the 35S-GTPγS binding assay can be 
shown in guinea pig brain (cerebral cortex).   
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B. Materials and Methods 
1. Materials 
1.1 Equipment 
Analytical balance Extend ED124S, Sartorius, Göttingen, Germany 
Analytical balance TE 610, Sartorius, Göttingen, Germany 
ARE Heating Magnetic Stirrer, VELP Scientifica srl, Usmate, Italy 
Cell Harvester IH 120, Inotech, Wohlen, Switzerland 
Chromatographic columns: Phenomenex Luna 2.5-μm C18 (2)-HST column, 100 mm × 2 mm, 
combined with a SecurityGuard precolumn C18, 4 mm × 2 mm; Phenomenex, 
Aschaffenburg, Germany 
CTC HTC PAL autosampler, CTC Analytics AG, Zwingen, Switzerland 
Dispensette® Dispenser 2 ml and 5 ml, Brand, Wertheim, Germany 
Dissecting set, Everhards, Meckenheim, Germany 
Electrophoresis, Constant Power Supply 2297 MACRODRIVE 5 LKB Bromma, Sweden 
Guillotine, self-made by Institute workshop artisan, Bonn, Germany 
Homogeniser Potter‐Elvehjem Braun 853302/4, B. Braun, Melsungen, Germany 
Laboratory shaker Duomax 1030, Heidolph, Schwabach, Germany 
LC system Agilent 1200 series, Agilent, Waldbronn, Germany 
Liquid scintillation counter LS 6000 TA, Beckman Coulter, Fullerton, CA, USA 
Mass spectrometer 5500 QTrap triple-quadrupole linear ion trap equipped with Turbo V  
Ion Source, AB SCIEX, Darmstadt, Germany 
Microwave, Panasonic NN-E201WBGPG, France 
Multipette Nr. 4710, Eppendorf, Hamburg, Germany 
pH meter Five Easy, Mettler Toledo, Gießen, Germany 
Pipettes Eppendorf Research, Eppendorf, Hamburg, Germany 
Refrigerated centrifuge 5402, Eppendorf, Hamburg, Germany 
Refrigerated centrifuge 5804, Eppendorf, Hamburg, Germany 
Refrigerated centrifuge Type J2‐21, Beckman, München, Germany 
Spectrophotometer (RNA concentration), SmartSpec Plus Bio-Rad, München, Germany 
Tabletop centrifuge Type 5415C, Eppendorf, Hamburg, Germany  
Thermal cycler, MyCycler, Bio-Rad, München, Germany 
ThermoMixer compact, Eppendorf, Hamburg, Germany 
Tissue homogeniser/grinder Precellys 24, Berlin Technologies, Montigny-le-Bretonneux, France 
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Tissue Lyser, Qiagen, Hilden, Germany 
TSE ActiMot System, Open Field Frames (42 cm x 42 cm x 28 cm), TSE Systems GmbH,  
Bad Homburg, Germany 
UV chamber, Power Shot G5, Canon, Krefeld 
UV/VIS Spektrophotometer BioPhotometer, Eppendorf, Hamburg, Germany 
Vacuum Controller IH 195, Inotech, Wohlen, Switzerland 
Vapotherm mikro 96, Barkey, Leopoldshoehe, Germany 
Voltage source PowerPac 300, Bio‐Rad, München, Germany 
Vortexer ZX3, VELP Scientifica srl, Usmate, Italy 
Waterbath and shaker 4010, Köttermann, Hänigsen, Germany 
Waterbath, IKA IS2 IKA Laboratories Staufen, Germany 
 
1.2 Software and databases 
ACD/ChemSketch (freeware), Advanced Chemistry Development, Toronto, Canada 
BLAST Basic Logical Alignment Tool and Nucleotide database, National Center for Biotechnology 
Information (NCBI), U.S. National Library of Medicine, Bethesda, MD, USA 
GraphPad Instat 1.0 and Prism 5.0, GraphPad, San Diego, CA, USA 
Mass spectrometry Software Analyst®, AB SCIEX, Framingham, MA, USA 
Mendeley Desktop, Mendeley Ltd., London, United Kingdom 
Microsoft Office 2007, Microsoft Corporation, Redmond, WA, USA 
Photo edition: Irfan View 4.00 (freeware), http://www.irfanview.com 
Photo documentation system, Power Shot G5, Canon, Krefeld, Germany 
PubMed MEDLINE, http://www.ncbi.nlm.nih.gov/pubmed 
Radioactivity Calculator QuickCalc, http://www.graphpad.com/quickcalcs/radcalcform.cfm 
Sequence Manipulation Suite: PCR Primer Stats, http://www.bioinformatics.org, Paul Stothard, 
University of Alberta, Canada 
TSE ActiMot System, software for Windows, TSE Systems GmbH, Bad Homburg, Germany 
 
1.3 Disposables and chemicals 
1.3.1 Disposables 
Cannula disposable, Sterican G26 and G27, B. Braun Melsungen AG, Melsungen, Germany 
Centrifuge tubes 15 ml and 50 ml, Sarstedt, Nümbrecht, Germany 
Cuvettes 2 ml 67.741, Sarstedt, Nümbrecht, Germany 
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Folded filter 597½, Schleicher & Schuell, Dassel, Germany 
Glass microfiber filters GF/B Nr. 1821915, Whatman, Maidstone, UK 
Microcuvettes 100 µl, Sarstedt, Nümbrecht, Germany 
Midi-Vials™ 8ml, Perkin-Elmer, Boston, MA, USA 
MT/DW 96-well plates, Thermo Fischer Scientific, Braunschweig, Germany 
Multipettes tips Combitips®, Eppendorf, Hamburg, Germany 
Parafilm PM‐956, Pechiney Plastic Packaging, Chicago, IL, USA 
Pipette tips, Sarstedt, Nümbrecht, Germany 
Pipette tips, sterile with filter, Axygen, Union City, CA, USA 
Reaktion tubes 2 ml, Biozym, Oldendorf, Germany 
Reaktion tubes Safe‐Lock 0.5 ml, 1.5 ml and 5 ml, Eppendorf, Hamburg, Germany 
Syringes 1 ml, BD Plastipak, Heidelberg, Germany 
 
1.3.2 Chemicals 
Chemical structures of all essential ligands used in 35S-GTPγS binding studies or drugs 
administered to mice are presented in Table 2 (cannabinoid receptor ligands), Table 3 (JZL 184), 
and Table 4 (histamine receptor ligands). 
 
β‐Mercaptoethanol, Sigma Aldrich Chemie, Steinheim, Germany 
9-Tetrahydrocannabinol, (100 mg/ml stock in ethanol 96 %), THC-Pharm GmbH, Frankfurt am 
Main, Germany 
4-Methylhistamine dihydrochloride, Biotrend, Cologne, Germany 
Absolute alcohol (ethanol 96%), KMF Laborchemie, Lohmar, Germany 
Acetonitrile, LC-MS grade solvent, CHROMASOLV®, Sigma Aldrich, Munich, Germany 
Adenosine deaminase, Roche, Mannheim, Germany 
Agarose, Carl Roth, Karlsruhe, Germany 
Boric acid, Roth, Karlsruhe, Germany 
BSA (Bovine Serum Albumin), Sigma‐Aldrich Chemie, Steinheim, Germany 
Coomassie‐Brilliant Blue G 250, Serva, Heidelberg, Germany 
CP 55,940, Biotrend, Cologne, Germany 
Cremophor, Sigma Aldrich Chemie, Steinheim, Germany 
DMSO (dimethyl sulfoxide), Merck KGaA, Darmstadt, Germany 
EDTA (ethylene diaminetetraacetic acid), Carl Roth, Karlsruhe, Germany 
EGTA (ethylene glycol tetraacetic acid), Carl Roth, Karlsruhe, Germany 
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Endocannabinoids and related lipids, Cayman Chemicals, Ann Arbor, MI, USA: 
   2-AG (2-arachidonoylglycerol),  
  AEA (anandamide), 
  AA (arachidonic acid), 
  OEA (oleylethanoloamide), 
  PEA (palmitoylethanolamide), 
 and their deuterated analogues:  2-AG- d5,  
  AEA-d4, 
  AA- d8;   
  OEA- d2,  
  PEA- d4  
Ethidium bromide 10 mg/ml, Bio‐Rad, Munich, Germany 
Ethylacetate, LC-MS grade solvent CHROMASOLV®, Sigma Aldrich, Munich, Germany 
Ficoll® PM 400, Sigma Aldrich Chemie, Munich, Germany 
Formic acid, LC-MS grade solvent CHROMASOLV®, Sigma Aldrich, Munich, Germany 
GDP (guanosinediphosphat sodium salt), Sigma Aldrich Chemie, Steinheim, Germany 
GTPγS Li4 (guanosine 5‘-O-[gamma-thio]triphosphate tetralithium salt), Sigma Aldrich Chemie, 
Steinheim, Germany 
Hexane, LC-MS grade solvent CHROMASOLV®, Sigma Aldrich , Munich, Germany 
Hydrochloric acid 1 M, KMF Laborchemie, Lohmar, Germany 
JNJ-7777120 – synthesized and kindly given by Prof. H. Stark and co-workers, Institute for 
Pharmaceutical and Medicinal Chemistry, Heinrich Heine University of Düsseldorf, 
Germany 
JZL 184, Biotrend, Cologne, Germany 
Lumagel-Safe® (scintillation liquid), Lumac LSC, Groningen, Netherlands 
Magnesium chloride hexahydrate, Merck KGaA, Darmstadt, Germany 
Ortho phosphoric acid 85%, Merck KGaA, Darmstadt, Germany 
R(+)‐WIN‐55,212‐2 mesylate salt, Sigma Aldrich Chemie, Steinheim, Germany 
R-α-Methylhistamine dihydrogenmaleate – synthesized and kindly given by Prof. W. Schunack, 
Institute of Pharmacy, Free University in Berlin, Germany 
Saline isotonic solution 0.9 % Braun, B. Braun Melsungen AG, Melsungen, Germany 
Sodium bicarbonate, KMF Laborchemie, Lohmar, Germany 
Sodium chloride, Carl Roth, Karlsruhe, Germany 
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ST-1006 – synthesized and kindly given by Prof. H. Stark and co-workers, Institute for 
Pharmaceutical and Medicinal Chemistry, Heinrich Heine University of Düsseldorf, 
Germany 
Sucrose, Merck KGaA, Darmstadt, Germany 
Thioperamide hydromaleate, Schering-Plough Reserch, Bloomfield, NJ, USA 
TrackltTM 100 bp DNA ladder, Invitrogen Life Technologies, Carlsbad, CA, USA 
Tris‐Base, Pufferan®, Carl Roth, Karlsruhe, Germany 
Tris‐HCl, Pufferan®, Carl Roth, Karlsruhe, Germany 
Substances were dissolved depending on solubility and experimental conditions: in distilled 
water, DMSO, ethanol or reaction buffer or suspended in cremophore and saline. Dilution series 
for binding experiments were prepared with reaction buffer and, in the case of cannabinoids 
with reaction buffer with 0.5 % BSA. 
Type Structure MW [g/mol] Function 
Synthetic 
 
125.17 H4 agonist 
 
125.17 H3 agonist 
 
277.75 H4 (partial) 
agonist 
 
367.28 H4 partial 
agonist 
 
292.44 H3 
antagonist 
Table 4. Chemical structures of histamine H3 and H4 receptor ligands. 
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1.3.3 Injections 
All injections were administered intraperitoneally (i.p.), in a volume of 0.1 ml per 10 g of mouse 
body weight. 
9-THC injections: 
Dose to mouse [mg/kg] THC stock [100 mg/ml] Cremophor [ml] Saline [ml] 
0 = Control (Vehicle) (0.1 ml of ethanol) 0.5 9.4 
10 0.1 ml (100 µl) 0.5 9.4 
Table 5. Composition of 9-THC solution. 
 
JZL 184 injections: 
Dose to mouse [mg/kg] JZL-184 [mg] Cremophor [ml] Saline [ml] 
0 = Control (Vehicle) 0 1 9 
4 4 1 9 
10 10 1 9 
40 40 1 9 
Table 6. Composition of JZL 184 solution. 
 
1.3.4 Buffers and solutions 
Buffers and solutions to work with tissues 
Phosphate buffered saline (PBS) 
NaCl  137 mM  
Na2HPO4  8 mM  
KH2PO4  1.4 mM  
KCl  2.7 mM  
Dissolved in H2O and adjusted to pH 7.4 with HCl. 
Buffers and solutions to work with protein 
Tris-EDTA buffer (TE buffer) 
Tris 50 mM 
EDTA 5 mM 
pH 7.5 at 4 C 
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Tris-EDTA-sucrose buffer for membrane preparation (TE-sucrose buffer): 
10.27 % sucrose, in TE buffer: 
Sucrose 10.27 g 
TE buffer ad  100 g 
 
Bradford stock solution 
Coomassie Brilliant Blue G 250 0.1 g 
Ethanol 50 % (V/V) 50 ml 
Phosphoric acid 85 % 100 ml 
Water bidest.  ad  250 ml 
The stock solution has to be stored for four weeks at 4 °C before first use. 
 
Bradford working solution 
Bradford stock solution 1 volume fraction 
Water bidest.  15 volume fractions 
Bradford working solution has to be prepared fresh by just before use and filtrated through 
folded paper filter. 
Buffers and solutions for 35S-GTPγS binding experiments 
Tris-EGTA reaction buffer 
Tris 50 mM 
EGTA 1 mM 
MgCl2 3 mM 
NaCl 100 mM 
pH 7.4 at 4 °C 
Addition of 0.5 % BSA needed to dissolve lipophilic cannabinoids 
 
Tris-EDTA wash buffer (TE buffer)  
Tris 50 mM 
EDTA 5 mM 
pH 7.5 at 4 °C 
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Buffers and solutions to work with nucleic acids 
 
The RNA isolation was conducted using NucleoSpin® kit. Following buffers were provided as a 
kit contents: 
Lysis buffer RA1, 
Wash buffer RAW2, 
Lysis buffer RA3, 
MDB (membrane desalting buffer), 
Reaction buffer for rDNase, 
rDNase, RNase-free. 
 
rDNase reaction mixture (NucleoSpin®) 
Reconstituted rDNase 10 µl 
Reaction buffer for rDNase 90 µl 
 
MasterMix for RT (reverse transcriptase) reaction 
10 x buffer RT 2 µl 
dNTP Mix 5 mM 2 µl 
Oligo(dT)18 Primer 10 µM 2 µl 
RNase inhibitor 10 U/µl 0.5 µl 
Omniscript RT 1 µl 
Final volume 7.5 µl 
Volumes listed above refer to a single sample. A volume of MasterMix for more samples was 
calculated using the formula: [µl] x (n+1), n=amount of samples. 
RNase inhibitor 10 U/µl: RNase inhibitor Promega 40 U/µl was diluted to the concentration of 
10 U/µl in ice-cold 1 x buffer RT. 1 x buffer RT was diluted 1:10 using 10 x buffer RT and RNase 
free water. 
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MasterMix for PCR 
10 x PCR buffer (-MgCl2) 5 µl 
MgCl2 50 mM 1.5 µl 
dNTP 10 mM each 1 µl 
Primer sense 10 µM 2.5 µl 
Primer antisense 10 µM 2.5 µl 
Taq DNA Polymerase 5 U/µl 0.3 µl 
Sterile water ad 45 µl 
Volumes listed above refer to a single sample. The amount of MasterMix for more samples was 
calculated using the formula: [µl] x (n+1,5), n=amount of samples. 
For primer sequences, see Table 12. 
 
5 x TBE (Tris borate EDTA) buffer 
Tris 54.9 g 
Boric acid 27.5 g 
EDTA 4.65 g 
Water bidest. ad 1000 ml 
To obtain 0.5 x TBE buffer, the 5 x TBE buffer was diluted 1:10 with water bidest. 
Loading buffer for PCR (polymerase chain reaction) 
Ficoll 400  1.5 g 
1 % (w/v) BPB  2.5 ml 
5 x TBE buffer  1 ml 
Water bidest. ad 10 ml 
 
Solutions used for endocannabinoid extraction and quantification by LC-MRM (liquid 
chromatography-multiple reaction monitoring) 
 
Tissue extraction: 
Aqueous solvent / homogenisation buffer: 
Formic acid 0.1 M 
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Organic solvent / extraction buffer:  
Ethylacetate:  9 volume fractions 
n-Hexan 1 volume fraction 
 
Deuterated Mix, ISTDs (internal standards), final concentrations: 
AEA-d4 4 ng/ml 
2-AG-d5 2000 ng/ml 
AA-d8 40000 ng/ml 
MAEA (methanandamide) 2 ng/ml 
OEA-d2 10 ng/ml 
PEA-d4 20 ng/ml 
1-AG-d5 100 ng/ml 
Spike solution: 
Deuterated Mix 1 volume fraction 
Acetonitrile 19 volume fractions 
 
LC-MRM solvents: 
Solvent A: 
0.1 % formic acid in water 
Solvent B: 
0.1 % formic acid in acetonitrile 
 
1.3.5 Radiochemicals 
35S-GTPγS (guanosine 5-[-35S]thiophosphate, triethylammonium salt, specific activity: 1250 
Ci/mmol), Perkin Elmer, Boston, MA, USA (for chemical structure, see Table 9). 
 
1.3.6 Kits 
NucleoSpin ® RNA, Macherey-Nagel, Düren, Germany 
Omniscript Reverse Trancriptase Reaction kit, Quiagen, Hilden, Germany 
Pierce BCA protein assay kit, Pierce Biotechnology, IL, Rockford, USA 
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1.4 Animals 
Animal care and conduction of experiments followed all applicable international and 
institutional guidelines. Permission number: Az 87-51.04.2011.A038 (obtained from the local 
ethical committee (Bezirksregierung Köln). 
Animals were kept in the House of Experimental Therapy, University of Bonn. 
 
CB1-/- knockout and CB1-/-/CB2-/- double knockout mice, Prof. A. Zimmer, Institute of Molecular 
Psychiatry, Bonn, Germany 
C57BL/6J wild type mice, Charles River Laboratories, Sulzfeld, Germany 
CD-1 mice, male, Charles River Laboratories, Sulzfeld, Germany 
Guinea pig, Dunkin‐Hartley, male, 8-16 weeks, Charles River Laboratories, Sulzfeld, Germany 
Age or weight of mice used for experiments was specified in the relevant sections in chapter 
“Methods” (B.2). 
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2. Methods 
2.1 Mouse treatment 
2.1.1 9-THC treatment 
Male C57BL/6J wild type mice of two age groups:  
- adolescent (6-8 weeks old, 8 animals per group / n=8) and  
- old (12 months old, 8-10 animals per group / n=8-10)  
were treated with i.p. injections of 9-THC or its vehicle (for composition of solutions, see  
Table 5), twice a day, approximately at 8.00 a.m. and about 16.30 p.m. Animals were treated 
with 10 mg/kg 9-THC or vehicle, as shown in Table 7. On “Day 4” animals were treated only 
once in the morning; 24 h later (“Day 5”), they were challenged with 9-THC or received vehicle 
instead. The Open Field Test was conducted 40 min after injection to measure the effect of the 
challenge dose on mice motility. The treatment schedule was modified from Bass and Martin 
(2000) and is presented in Table 7 below. 
Treatment 
group 
Day 1- Day 3 Day 4 Day 5 
a
d
o
le
sc
e
n
t 
  a
n
d
   
o
ld
 
Control 
a.m.: vehicle 
p.m.: vehicle 
a.m.: vehicle 
24 h break 
a.m.: vehicle 
Open Field Test 
Acute 
a.m.: vehicle 
p.m.: vehicle 
a.m.: vehicle 
24 h break 
a.m.: 10 mg/kg Δ9-THC 
Open Field Test 
Chronic 
a.m.: 10 mg/kg Δ9-THC 
p.m.: 10 mg/kg Δ9-THC 
a.m.: 10 mg/kg Δ9-THC 
24 h break 
a.m.: 10 mg/kg Δ9-THC 
Open Field Test 
 P r e - t r e a t m e n t Challenge dose  
Table 7. Induction of Δ9-THC tolerance in C57BL/6J mice. Adolescent or old mice received one (“Acute”) or repeated 
i.p. injections of 10 mg/kg Δ9-THC (“Chronic”). Control groups (“Control”) were treated with vehicle only. 
 
2.1.2 JZL 184 treatment 
Male CD-1 mice weighing about 30 g (8 animals per group / n=8) were treated once a day with 4, 
10 or 40 mg/kg body weight JZL 184 or with vehicle by i.p. injections (for composition of 
solutions, see Table 6). Treatment lasted for 1, 3 or 14 days (for treatment schedule, see  
Table 8). Animals were killed 24 h after the last injection by decapitation and each hemisphere 
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of the hippocampus was frozen separately on dry ice and stored at -80 C for 35S-GTPS binding 
studies (left hemisphere) and LC-MS/MS (LC-MRM) (right hemisphere). 
Treatment 1 Dose 3 Doses 14 Doses 
Vehicle 8 mice 8 mice 8 mice 
JZL 184 4 mg/kg 8 mice 8 mice 8 mice 
JZL 184 10 mg/kg 8 mice 8 mice 8 mice 
JZL 184 40 mg/kg 8 mice 8 mice 8 mice 
 Decapitation 24 h after last injection 
Table 8. JZL 184 treatment of CD-1 mice. Four, 10 or 40 mg/kg JZL 184 was administered i.p. to mice (n=8 per group) 
for 1, 3 or 14 days. 
 
2.2 Behavioural studies: Open Field Tests 
The Open Field experiments were conducted in collaboration with PD Dr. A. Bilkei-Gorzo,  
PD Dr. I. Rácz and K. Michel from the Institute of Molecular Psychiatry, University of Bonn within 
the DFG (Deutsche Forschungsgemeinschaft) Research unit FOR 926 (Forschergruppe 926). 
2.2.1 Experimental procedure 
The Open Field Test provides information about motor activity and exploratory behaviour of 
mice (Walsh and Cummins 1976). In this study, adolescent and old C57BL/6J wild type mice 
were treated according to Table 7 and as described in section B.2.1.1. Forty min after injection of 
the challenge dose, animals were placed in the middle of the open field frame and their motor 
activity was tracked by an automatic monitoring system (ActiMot) for 10 min in the darkness 
(infrared). Animals were tested in the Open Field Apparatus in a random order. 
2.2.2 Experiment evaluation 
Three parameters, i.e., distance travelled [m], rearing number and resting time [s], were 
measured by the ActiMot System. Using the GraphPad Prism 5 software means  SEM were 
determined and presented as columns; the effect of age and treatment schedule was analyzed as 
well. 
Furthermore, to simplify comparison of the data, the results obtained with the ActiMot System 
were normalized to “% of activity suppression” values. First, the performance of the Δ9-THC-
treated mice was expressed in % of the vehicle treated mice (control group) (see Equation 1). 
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Equation 1. Calculation of percentage value of activity (% activity) of acute and chronically 9-THC treated mice. 
Subsequently, the “% activity suppression” was calculated as the difference between vehicle 
(100 %) and analyzed treatment group (as shown in Equation 2). However, Equation 2 
corresponds only to the parameters “Distance travelled” and “Rearing number”, which measure 
animals’ activity. 
 
Equation 2. Calculation of the suppression of activity (% activity suppression), relevant for “Distance travelled” and 
“Rearing number”. 
In case of the parameter “Resting time”, which directly corresponds to the inhibition of activity 
(% activity becomes % inhibition), the “% of activity suppression” was calculated as shown in 
Equation 3. 
 
Equation 3. Calculation of the suppression of activity (% activity suppression), relevant for “Resting time”. 
The use of “% Activity suppression” simplifies analysis of behavioural tests. All conversions were 
conducted using GraphPad Prism 5 software. Mean values  SEM of “% Activity suppression” 
were presented as column bar graphs for the two age and the two treatment groups. 
 
2.3 Receptor binding experiments 
2.3.1 Theoretical background 
The 35S-GTPS binding assay provides information about activity and function of the G protein-
coupled receptors (GPCRs) and is one of the most sensitive methods to determine the efficacy of 
the ligands interacting with GPCRs. The assay measures the earliest receptor-mediated events 
(Lazareno 1999; Harrison and Traynor 2003; Breivogel 2006; Strange 2010) and is based on the 
GPCR activation cycle (see Figure 8 and Figure 9). 
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Figure 8. G protein-coupled receptor activation cycle. 
The GPCR cycle starts with the activation of the GPCR by the agonist. Activation of the receptor 
causes that the inactive G protein, consisting of the Gα subunit and Gβγ heterodimer in which 
GDP is bound to the Gα subunit, changes its conformation and GDP is released and replaced by 
GTP. The GDP-GTP exchange is a crucial step which, depending on the G protein type, influences 
numerous signalling pathways such as cAMP production. The conformation change of the  
Gα subunit decreases the affinity of the receptor–Gα–Gβ complex causing dissociation of these 
three components. Furthermore, the G protein possessing intrinsic GTPase activity hydrolyses 
GTP to GDP and inorganic phosphate (Pi) (see Figure 8, modified from Harrison and Traynor 
2003 and Strange 2010). Then, the Gα subunit and Gβ re-associate and the GPCR cycle is over. 
 
Figure 9. G protein-coupled receptor cycle under physiological conditions (A) and under the influence of 35S-GTPS 
(B).  
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When 35S-GTPS is added to the reaction mixture, it binds to the Gα subunit instead of non-
radioactive GTP (Figure 9B). 35S-GTPS contains a sulphur instead of an oxygen atom at the  
 phosphate group (for chemical structure, see: Table 9). So, this structure cannot be hydrolysed 
by the GTPase of the Gα subunit and the formed complex accumulates in the reaction mixture. 
Since the Gα remains associated with the cell membrane, the amount of the G protein-35S-GTPS 
complex can be measured and analyzed after filtration through a glass-fibre filter in which the 
cellular membrane, Gα and 35S-GTPS remain (Harrison and Traynor 2003).  
Type Structure MW [g/mol] 
Radiolabelled 
nucleotide 
 
539.2 
Table 9. Chemical structure of the 35S-GTPγS, radiolabelled nucleotide used in binding experiments. 
2.3.2 Experimental procedures 
Membrane preparation 
Animals were killed by decapitation. The brain was removed using a dissecting set, 
hippocampus or cortex was isolated on the cold (4 C) block, frozen on dry ice in preconditioned 
ice-cold reaction tubes and stored at -80 C or homogenized immediately after preparation. All 
procedures described below were conducted at 4 C (centrifugation) or on ice. 
For homogenization, frozen tissue (40 - 80 µg) was transferred into 1000 µl of ice-cold TE-
sucrose buffer. Homogenization was conducted using a Potter-Elvehjem homogenizer (10 
strokes per minute, 1200 rpm). The homogenate was transferred into a 1.5 ml reaction tube and 
the Potter vessel was rinsed with a further 500 µl of ice-cold TE-sucrose buffer. The tissue 
suspension was centrifuged for 10 min at 1500 x g. The supernatant was transferred into a new 
Eppendorf tube and centrifuged for 25 min at 20 000 x g. Subsequently, the supernatant was 
removed and the residual pellet re-suspended in 1000 µl TE buffer and centrifuged for 10 min at 
20 000 x g (first wash step). The wash step was repeated, the supernatant discarded and the 
final pellet briefly homogenized in 500 µl Tris-EGTA reaction buffer using a Potter-Elvehjem 
homogeniser at 1200 rpm. Triplicates of 10 µl of protein suspension were used for 
determination of protein concentration (see below); the rest of the protein suspension was 
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frozen and stored at -80 C. For 35S-GTPγS binding experiments, the protein suspension was 
thawed and diluted to the needed protein concentration with Tris-EGTA reaction buffer. 
Determination of protein concentration 
Determination of the protein concentration using the Bradford assay (Bradford 1976) is based 
on the reaction of the Coomasie Brilliant Blue G-250 dye with protein contained in the analyzed 
suspension. The Coomasie Brilliant Blue G-250 dye in anionic form binds to positively-charged 
amino-groups (mainly: arginine, lysine and histidine) of the proteins causing a change in reagent 
colour (Compton and Jones 1985). The red-brown colour of the Bradford-stock solution changes 
to blue in the presence of protein and the intensity of this blue colour increases with an 
increasing amount of the protein in the tested sample. The intensity of the blue colour can be 
measured using a UV-photometer. The protein concentration was determined using a calibration 
curve. 
As shown in Table 10, the calibration curve was prepared with BSA 0.1 µg/µl solution and 
distilled water to obtain standards of 1, 2.5, 5, 7.5, 10 and 15 µg of protein and distilled water as 
a control. To estimate the protein concentration, 10 µl of the test sample in Tris-EGTA buffer was 
added to 140 µl of distilled water; finally 2 ml of Bradford working solution were added to all 
sample and calibration curve cuvettes and mixed properly. The measurement of the absorbance 
(OD) was conducted at 595 nm, 5 to 30 min after addition of the Bradford working solution to 
the cuvettes. 
The protein concentration was calculated using a calibration curve. The OD values of known 
standards were compared with the ODs of the samples. 
BSA 0.1 µg/µl [µl] Water dist. [µl] BSA standard [µg]  
0 150 0 C
alib
ratio
n
 cu
rv
e 
10 140 1 
25 125 2.5 
50 100 5 
75 75 7.5 
100 50 10 
150 0 15 
10* 140 x 
Sam
p
le 
Table 10. Calibration curve and sample preparation for the Bradford assay.  
* - Here 10 µl of the sample was used instead, x – measured protein concentration [µg] in the sample. 
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35S-GTPS binding assay 
Previously homogenized protein suspension, (diluted to the final concentration) was  
pre-incubated for 10 min at 30 C with adenosine deaminase 0.004 U/ml to inactivate the 
endogenous adenosine. Removal of endogenous adenosine prevents the activation of adenosine 
receptors in the tissue. These receptors, expressed in many brain regions, among others in 
hippocampus or cerebral cortex, belong to the GPCR superfamily and activate Gi/Go proteins 
causing an increase in the basal binding effect of the tissue. By inactivation of the adenosine, 
basal binding decreases and the signal : noise ratio is significantly improved (Moore et al. 2000).  
All reagents were pre-diluted and/or solved in Tris-EGTA reaction buffer if not stated otherwise 
and pipetted into 2 ml reaction tubes in a 24-well plate to final volumes of 500 µl. Pipetting 
order, volumes and concentrations are shown in Table 11. 
Reagent Volume [µl] Concentration Comment 
Tris-EGTA* 300 - in all tubes 
GDP 50  30 µM in all tubes 
Ligand 50 0.0003 µM - 30 µM each concentration in triplicate 
Ligand* solvent 50 - control - total binding, in triplicate 
35S-GTPS 50 0.5 nM in all tubes 
GTPSLi4 50 10 µM unspecific binding, in triplicate 
Protein homogenate 50 5-10 µg/50 µl in all tubes 
Final volume 500  
Table 11. Reagents used in the 35S-GTPS binding assay.  
*Tris-EGTA buffer - if more than one ligand was used, the volume of reaction buffer was reduced accordingly;  
*Ligand - cannabinoids – diluted and solved in Tris-EGTA + 0.5 % BSA 
For the experiments with cannabinoids, Tris-EGTA reaction buffer with 0.5 % BSA has to be 
used. The lipophilic cannabinoids tend to adsorption to surfaces like glass or synthetic materials. 
Addition of 0.5 % BSA to the buffer prevents this effect. Washing the Cell-Harvester with Tris-
EGTA with 0.5 % BSA just before filtration serves the same purpose. 
Immediately after addition of the protein to the reaction mixture, the 24-well plate was covered 
with parafilm, briefly vortexed and placed into the water bath shaker for 1 h at 30 C. One hour 
after the start of incubation, the reaction was stopped by rapid vacuum filtration of the reaction 
mixture through a GF/B Whatmann filter using an Inotech Cell-Harvester. The residual pressure 
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was 400 mbar. The filter was washed three times with ice-cold TE-wash buffer and round filters 
(diameter of 1 cm) were punched by the Cell-Harvester. The latter were placed into scintillation 
vials and 4 ml of scintillation liquid (LumaGel) was pipetted into each vial; vials were shaken for 
12 h (overnight). The radioactivity (cpm) in the vials was determined using a Liquid Scintillation 
Counter (counting time of 5 min for each sample). 
2.3.3 Calculation of results 
A self-made Microsoft Excel spreadsheet was used to calculate unspecific and basal binding and 
GraphPad Prism 5 software served to calculate the effect of the ligand on the receptor. The 
results were presented in form of non-linear concentration-response curves as “% of specific 
35S-GTPS binding” or “cpm over basal binding”. All values were obtained in triplicate as cpm 
units and the mean values were used for calculations. 
To determine the basal binding, the unspecific binding was subtracted from the total binding 
value (Equation 4): 
 
Equation 4. Calculation of the basal binding of the receptor. 
To determine the effect of the ligand, unspecific binding was subtracted from the cmp value 
obtained for each concentration. To present the data in “cpm over basal”, basal binding was 
subtracted from each cpm value (Equation 5) and a non-linear regression analysis was 
performed (Hill slope = 1). X axis: molar concentration [M] versus Y axis: cmp over basal values. 
 
Equation 5. Calculation of cmp over basal. 
To calculate “% of specific 35S-GTPS binding”, basal binding (in cpm) was defined as 100%  
and the cpm value obtained for each ligand concentration was normalized to basal binding 
(Equation 6) followed by non-linear regression analysis (Hill slope = 1). X axis: concentration 
[M] versus Y axis: % of specific 35S-GTPS binding. 
 
Equation 6. Calculation of percent (%) of specific 35S-GTPS binding. 
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Recovery test 
Due to the relative short half time of the 35S isotope (87.6 days), the amount of radioactivity was 
adjusted before each experiment. The amount of radioactivity was calculated using GraphPad 
Radioactivity Calculator QuickCalcs; the recovery test was conducted in parallel. 
 
2.3.4 Calculation of potencies 
The potency of agonists was characterized using pEC50 values. The pEC50 is defined as the 
negative logarithm of the concentration of the agonist which induces the half-maximal effect. 
The pEC50 values were determined from the concentration-response curves using 
GraphPadPrism software. 
The potency of a given antagonist was characterized by its pA2 value, which is defined as the 
negative logarithm of the antagonist concentration at which the concentration-response curve of 
an agonist is shifted to the right by a factor of two (Arunlakshana and Schild 1997). The pA2 
value was determined according to the formula in Equation 7: 
 
Equation 7. Antagonist potency calculation: pA2 value. [A’] and [A] are the EC50 values of the agonist obtained in the 
presence and absence of the antagonist, respectively; [B ] is the antagonist concentration 
 
2.4 Determination of endocannabinoids by liquid chromatography – 
multiple reaction monitoring 
Detection and quantification of endocannabinoids using LC-MS/MS with MRM was conducted in 
collaboration with Dr. Laura Bindila and Claudia Schwitter at the laboratory of Prof. Dr. Beat 
Lutz, Institute of Physiological Chemistry, University Medical Center of the Johannes Gutenberg-
University in Mainz within the DFG Research unit FOR 926. 
Preparation, handling and measurement of the samples were conducted according to the 
recommendations published by Vogeser and Schelling (2007) and Vogeser and Seger (2010). 
For technical data, see section B.1.1. For chemicals and composition of solvents see section 
B.1.3.2 and B.1.3.4. Detailed LC and MS parameters were reported by Wenzel et al. (2013). 
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2.4.1 Sample preparation 
Hippocampus samples (right hemisphere) of 96 CD-1 male mice pre-treated as described in 
section B.2.1.2, according to the Table 8, were isolated, rapidly frozen at dry ice in pre-cooled 
reaction tubes and stored at -80 C. 
For the analysis, tissue samples were transferred into preconditioned cold extraction tubes; ice-
cold steel balls were placed into each tube, 50 µl of ice-cold spiking solution containing internal 
standards and 300 µl of aqueous solvent (0.1 M formic acid) were pipetted using a pipetting 
machine and homogenized using a Precellys 24 homogenizer. Subsequently, 300 µl of ice-cold 
organic solvent were added to each tube using a multistepper pipette and samples were run in 
Tissue lyser for 30 sec at 30 Hz to extract endocannabinoids.  
To separate the organic and aqueous phase, the tubes were centrifuged for 10 min at 5000 x g 
and kept at -20 C for 10-20 min to freeze the aqueous phase at the bottom of the extraction 
tube. The aqueous phase was stored for protein determination (Pierce BCA protein assay kit). 
The upper, organic phase (supernatant) was transferred into a MT/DW 96-well plate, 
evaporated to dryness in a Vapotherm to dryness and stored at – 20 C until analysis. The 
samples were reconstituted in 50 µl of acetonitrile/H2O (1:1) directly before loading to the 
chromatographic column. 
 
2.4.2 Chromatographic conditions 
Extracted endocannabinoids and AA were separated by injection of 20 µl samples (autosampler) 
on a Phenomenex Luna 2.5-μm C18 (2)-HST column, 100 mm × 2 mm, combined with a 
SecurityGuard precolumn C18, 4 mm × 2 mm with Solvent A and Solvent B (for composition see 
section B.1.3.4.). 
 
2.4.3 Mass spectrometry - MRM 
Endocannabinoids and AA separated using LC were analyzed by MRM on a 5500 QTrap triple-
quadrupole linear ion trap mass spectrometer equipped with a Turbo V Ion Source (AB SCIEX) 
coupled to the LC system. Concentrations of AEA, 2-AG and AA were normalized to the protein 
content of each sample. 
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2.5 Detection of H4 receptor mRNA expression 
PCR experiments were conducted in collaboration with Margarita Fuhrmann and Prof. Dr. Kurt 
Racké from the Institute of Pharmacology and Toxicology, University of Bonn. 
2.5.1 RNA purification from guinea pig cerebral cortex and spleen tissue 
A male Dunkin‐Hartley guinea pig was killed by decapitation. The cortex and spleen were 
dissected immediately after decapitation, frozen on dry ice and stored at -80 C. The processing 
of the tissues was performed using the NucleoSpin® protocol, according to the manufacturer. 
Briefly, up to 30 mg of the tissue were thawed in the presence of 600 µl of RA1 buffer (RA1 
buffer lyses the tissue and prevents RNA degradation by RNases) and disrupted using a Potter-
Elvehjem homogenizer until a homogeneous tissue suspension was obtained. Subsequently,  
3.5 µl of β-mercaptoethanol were added. Tissue was vortexed and filtrated through a 
NucleoSpin® filter-ring placed in the collection tube by centrifugation at 11 000 x g for 1 min. 
This step reduces the viscosity of the lysate. To adjust the RNA binding conditions, 600 µl of 
ethanol were added to the filtrate and mixed properly with the pipette. The succeeding 
centrifugation of the lysate through the silica membrane of the NucleoSpin® RNA column at  
11 000 x g for 30 s resulted in RNA binding to the silica membrane. The addition of 350 µl of 
MDB and centrifugation at 11 000 x g for 1 min desalted the membrane. That step makes the 
rDNA digestion more effective. The DNA digestion was followed by applying of 95µl of rDNase 
reaction mixture onto the middle of the silica membrane of the column. The mixture was 
incubated for 15 min at room temperature. 
Subsequent steps were conducted to wash and dry the silica membrane. First, 200 µl of the  
RAW 2 buffer (to inactivate the rDNase) were added to the column and centrifuged at 11 000 x g 
for 30 s. The column was transferred from the collection tube into another 2 ml tube. In a second 
wash step, 600 µl of RA3 buffer were added to the column and centrifuged at 11 000 x g for a 
further 30 s; the column was transferred again into the previous collection tube. Final wash by 
addition of 250 µl of RA3 buffer and centrifugation at 11 000 x g for 2 min caused complete 
drying of the silica membrane. The highly pure RNA was eluted from the membrane through 
addition of 60 µl of RNase-free water, followed by centrifugation through the membrane at  
11 000 x g for 1 min. Gained RNA eluate was directly used for the reverse transcriptase reaction 
or stored at -80 C. 
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2.5.2 Determination of RNA concentration 
To determine the concentration of the RNA, the absorbance (A260) of the solution was measured 
using a spectrophotometer at a wavelength of 260 nm. The calculation of the RNA concentration 
is based on the known absorbance value of A260 = 1, which corresponds to 40 µg/ml RNA. 
To calculate the amount of the RNA, the A260 value of the measured RNA solution was multiplied 
by 40 µg/ml and by the dilution factor (Equation 8). The final RNA amount [µg] in the solution 
was calculated using Equation 9. 
 
Equation 8. Calculation of the RNA concentration. 
 
 
Equation 9. Calculation of final RNA amount. 
The purity of the RNA solution was estimated by calculation of the A260/A280 ratio. An A260/A280 
value close to 2 indicates high purity of the RNA. 
 
2.5.3 Reverse transcriptase reaction 
Reverse transcriptase transcribes RNA to single-stranded cDNA (copy-DNA). The Omniscript 
Reverse Transcriptase Reaction kit was utilized to synthesize cDNA from the RNA of guinea pig 
spleen and cerebral cortex. 
The mixture of: 
Master mix 7.5 µl 
RNA sample 1 µg 
RNase free water ad  20 µl 
was incubated for 60 min at 37 C, then for 5 min at 93 C, shortly vortexed and immediately put 
on ice. Sterile water (80 µl) was added and samples were either directly used for PCR or stored 
at -20 C. All procedures except incubation were conducted on ice and sterile equipment was 
used. 
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2.5.4 Polymerase chain reaction using Taq DNA Polymerase 
During polymerase chain reaction, double-stranded DNA is synthesized from the cDNA template 
through the activity of the Taq DNA polymerase in the presence of the primers. Taq DNA 
polymerase is an enzyme isolated from Thermophilus aquaticus YT1. 
All primers were designed using the primer designing tool “Primer-BLAST” (National Center for 
Biotechnology Information, National Library of Medicine). The properties and suitability of the 
primers were tested with the “Sequence Manipulation Suite – PCR Primer Stats” 
(www.bioinformatics.org/sms2) and verified (based on Mülhardt 2003) in terms of: 
- Primer length (18-30 bases) 
- Melting temperature (55-80 C) 
- GC content (40–60 %) 
- GC clamp 
- Self-annealing 
- Product length (200-600 bp) 
Primers were synthesized by Eurofins MWG Operon, Edersberg, Germany.  
The sequences of the designed primers are listed in Table 12. 
 
Guinea Pig: H4 Receptor GAPDH 
Forward 5’ – AGA GAA ACT GAG CAG GTG CC – 3’ 5’ – TGA CCA CAG TCC ATG CCA TC – 3’ 
Reverse 5’ – GAG CCC AGC AAA TGG CAA AA – 3’ 5‘– GCT TAG AGT GGG GCA GTG AC – 3‘ 
Product length (bp) 344 567 
Table 12. Sequences and product length of primers used for the polymerase chain reaction. 
 
The reaction mixture was composed as follows: 
Sample cDNA 5 µl 
MasterMix for PCR 45 µl 
A negative control, 5 µl of sterile water were used instead of sample cDNA. For composition of 
the MasterMix for PCR, see section B.1.3.2. 
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The reaction was performed in a thermo cycler according to the following program: 
first denaturation 95 C, 3 min 
 denaturation 94 C, 45 sec 
 primer annealing (temperature - see Table 13), 30 sec 35 cycles 
 extension 72 C, 1 min 
final extension 72 C, 10 min 
hold 4 C 
 
Guinea Pig Cortex Spleen 
H4 Receptor 61.4 C 61.4 C 
GAPDH 63 C 63 C 
Table 13. Primer annealing temperatures. 
PCR products were shortly centrifuged and directly used for agarose gel electrophoresis or 
frozen at -20 C for later use. 
 
2.5.5 Agarose gel electrophoresis 
A 2 % (m/v) agarose gel was prepared as follows: 
Agarose  2 g 
0.5 x TBE buffer ad 100 ml 
Agarose was dispersed in a buffer; the mixture was heated in a microwave, avoiding boiling, till 
the agarose powder dissolved. To detect the DNA bands under UV light, addition of ethidium 
bromide is needed. Therefore, slightly cooled agarose solution was stained with  
3.5 µl of EtBr and then uncongealed agarose gel was transferred into a cast with a comb placed 
inside of it. The comb is necessary to create the wells. The gel in the cast was cooled for about  
1 h and used for electrophoresis. 
The PCR reaction products were mixed with 5 µl of loading buffer (for buffer composition, see 
section B.1.3.2). A component of the loading buffer, Ficoll 400, enhances the density of the 
samples so that the samples sink into the well. The dye bromophenol blue in the loading buffer 
allows to observe how fast the sample is running through the gel between negative and positive 
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charge. The 100 bp ladder pipetted into one of the gel wells provides the template which enables 
sizing of the bands.  
The gel was placed in the chamber filled with 0.5 x TBE buffer (running buffer) between 
negative and positive charge (wells on the side of negative charge). Pre-treated samples and the 
negative control (loading buffer only), each 45 µl, and the 100 bp DNA ladder in a volume of  
15 µl were pipetted into the wells of the gel. The electrophoresis was conducted at room 
temperature, at constant voltage of 100 V for 40 – 50 min. Negatively charged DNA fragments 
pass through the gel towards the cathode, whereas the smaller fragments pass faster and further 
than the larger ones. After separation of the bands, the gel was placed inside of the UV-chamber 
and the bands were visually detected. Digital photography was made and pictures were saved 
(Photo documentation system, Power Shot G5, Canon). Comparison of the sample bands with the 
100 bp ladder provides information about the detected fragments of genes. 
 
2.6 Statistics 
The statistical calculations were made using the GraphPad Prism 5 software. 
All results are presented as arithmetic mean (  ) ± standard error of the mean (SEM) of  
  experiments. The mean value was calculated as shown in Equation 10: 
 
Equation 10. Arithmetic mean calculation. xi, single sample values; n, number of single values measured. 
 
The standard deviation (SD), here designated as  , was calculated as shown in Equation 11: 
 
Equation 11. Standard deviation calculation. xi, single sample values; n, number of single values measured;   , mean. 
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The standard error of the mean (SEM) was calculated using Equation 12: 
 
Equation 12. Standard error of the mean calculation. s, standard deviation; n, number of single values measured . 
The Student’s t-test was used to analyze two unpaired sets of values. To compare three and more 
groups, the one-way analysis of variance (ANOVA) was performed. The F-test was made to 
compare the standard deviations of two groups. The standard deviation was squared to obtain 
variances.  
 
Equation 13. Calculation of variance. s, standard deviation. 
The F ratio corresponds to: 
 
Equation 14. F ratio calculation.  
The F ratio was calculated to compare variations among means of the analyzed groups. A large  
F value means that the variation between tested groups is higher than expected by chance.  
An F value close to 1.0 means that the groups do not differ. Furthermore, the P value was 
calculated to compare the groups and answer the question if the difference among analyzed data 
sets is significant. A large P value means that the differences between the groups are as expected 
by chance. A small P value means that the groups differ. In this thesis, P values less than 0.05 
were considered significant (see Table 14). 
P value Meaning Sign 
 0.05 not significant ns 
0.01 < 0.05 significant * 
0.001 < 0.01 very significant ** 
< 0.001 extremely significant *** 
Table 14. Significance levels. 
ANOVA only allows to see if there is any difference between groups on some variable. In order to 
check whether this group differs from that, a post-hoc test is necessary. Here the Tukey test was 
used to compare all pairs of groups, whereas the Bonferroni correction was used to compare 
only certain pairs of data sets (Curtin and Schulz 1998).  
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C. Results 
1. Effect of 9-THC on CB1 receptors 
This thesis was prepared to answer the question: Does aging influence the tolerance 
development after chronic 9-THC treatment in mice? For this purpose, both behavioural and 
biochemical experiments were conducted. The motor activity of the mice was measured using 
the Open Field Test. Subsequently CB1 receptor activity in hippocampus was examined in  
35S-GTPγS binding experiments, post mortem. 
In preliminary experiments, the proper dose of 9-THC was determined; treatment with  
3 mg/kg 9-THC did not elicit significant behavioural and binding effects (results not shown) so, 
the dose of 9-THC had to be increased to 10 mg/kg and the term “9-THC” corresponds to this 
dose in the rest of this section.  
 
1.1 Behavioural test: Open Field Test 
The effects of 9-THC on numerous species, among others on mice, are discussed in section A.1, 
(Martin et al. 1991) of this thesis. The suppression of the spontaneous activity (hypoactivity), 
plus hypothermia, analgesia and catalepsy are known as the tetrad test for cannabinoid activity 
(Chaperon and Thiébot 1999). The intensity of the animal reaction to cannabinoids can be 
measured using these parameters. In this thesis, the Open Field Test was used to observe the 
activity suppression in mice and to detect the tolerance development to 9-THC effects in mice 
chronically pre-treated with 9-THC. The results were compared between adolescent and aged 
groups. 
The results are presented as the distance travelled and the rearing number which are mouse 
activity markers (the higher the values, the higher the motor activity or exploring, respectively), 
whereas the resting time parameter illustrates the activity suppression (the higher the value, the 
lower the activity). 
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1.1.1 General 
The Open Field Test is a behavioural test used to measure the activity (motility) of the rodents. 
The mouse is placed in the middle of an open space surrounded by a wall, which prevents 
escape. The measured behaviour of the mouse provides information about its condition. The 
Open Field Test is widely used in animal psychology e.g. in ‘anxiety’ models (Prut and Belzung 
2003) and is a sensitive and relatively simple method to measure effects of pharmacological 
treatment (Choleris et al. 2001). A difficulty of this method is the reproducibility of the results, 
which depends on various parameters like housing of animals, transport of an animal to the 
open field frame from its home cage and many other immeasurable aspects (e.g. interaction of 
the animal with the experimenter) (Walsh and Cummins 1976). 
In this study, motor activity of two age groups of mice (adolescent and old) was measured in 
three different treatment models (acute, chronic and control) according to Bass and Martin 
(2000) with modifications. Subsequently, the Open Field Test was performed. Details are given 
in section B.2.1.1; for composition of the injections see Table 5 and for the treatment schedule 
see: Table 7. Briefly, animals in the acute group were pre-treated with vehicle and challenged 
with Δ9-THC, those in the chronic group were injected with Δ9-THC as pre-treatment and 
challenged with Δ9-THC, whereas the control group was injected with vehicle only. The 
parameters distance travelled [m], rearing number and resting time [s] were measured in an 
Open Field apparatus for 10 min in the darkness (infrared light) as described in section B.2.2. 
The parameters indicating motor activity, i.e. distance travelled (Figure 10A) and exploratory 
behaviour expressed as rearing number (Figure 10B), were suppressed in animals challenged 
acutely with Δ9-THC, compared to the control group. The repetitive pre-treatment with Δ9-THC 
(chronic) resulted in a lower decrease of activity after the Δ9-THC challenge dose than in the 
acutely treated group. However, Δ9-THC pre-treatment did not completely prevent the effect of 
the Δ9-THC challenge dose. The motor activity decrease in chronically treated animals compared 
to the vehicle treated controls was significant, but tended to be weaker than in mice after the 
acute Δ9-THC dose. Furthermore, the difference between the acute and chronic treatment group 
was significant for rearing behaviour (Figure 10B), but not for distance travelled (Figure 10A). 
The rearing number parameter seems to be very sensitive to Δ9-THC and points to tolerance 
development in mice after Δ9-THC pre-treatment. However, a tendency towards a decreasing 
response to Δ9-THC after chronic pre-treatment was also observed for “distance travelled”. 
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Figure 10. Open Field Test in C57BL/6J adolescent mice treated as shown in Table 7. Animal motor activity (distance 
travelled, A; rearing number, B) was tested in the Open Field apparatus for 10 min in the darkness (infrared). 
Treatment groups: Control – pre-treated and challenged with vehicle only; Acute – pre-treated with vehicle and 
challenged with 10 mg/kg Δ9-THC, Chronic – pre-treated and challenged with 10 mg/kg Δ9-THC. Means ± SEM from  
8 mice. One-way ANOVA with Tukey multiple comparison post-test: *p<0.05, ***p<0.001. 
 
The third parameter measured in the Open Field Test, resting time (that indicates a reduction of 
the motor activity of mice), was increased or tended to be increased in both groups challenged 
with Δ9-THC, compared to the vehicle treated control, as shown in Figure 11. The acute 
administration of the Δ9-THC to mice caused a significant increase in resting time compared to 
the vehicle-treated controls. The resting time of the mice pre-treated with Δ9-THC did not differ 
from control or from the acutely Δ9-THC treated group; however, there was a tendency towards 
tolerance development after chronic Δ9-THC treatment. 
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Figure 11. Open Field Test in C57BL/6J adolescent mice treated as shown in Table 7. The suppression of motor 
activity was tested in the Open Field apparatus for 10 min in the darkness (infrared). Treatment groups: Control – 
pre-treated and challenged with vehicle only; Acute – pre-treated with vehicle and challenged with 10 mg/kg Δ9-THC; 
Chronic – pre-treated and challenged with 10 mg/kg Δ9-THC. Means ± SEM from 8 mice. One-way ANOVA with Tukey 
multiple comparison post-test: ***p<0.001. 
 
To sum up, pre-treatment of mice with Δ9-THC resulted in tolerance to Δ9-THC effects in rearing 
behaviour. A tendency towards tolerance development after chronic Δ9-THC treatment was 
observed for the parameters distance travelled and resting time. 
 
1.1.2 Comparison of adolescent and old mice 
The next step in the experiments was the comparison of the activity level between adolescent 
and old mice, acutely and chronically treated with Δ9-THC. To standardize the results and 
simplify the comparisons, all parameters measured were normalized to the percent of activity 
(% activity; calculated as explained in section B.2.2, Equation 1). Moreover, activity suppression 
of acutely and chronically treated mice was normalized to the control group of the age-matched 
animals (% activity suppression; calculated as explained in section B.2.2, Equation 2 and 
Equation 3). 
The age had no influence on distance travelled and resting in control animals (not treated with 
Δ9-THC) whereas the third parameter, rearing number, was reduced by ~ 50 % in old age 
(Figure 12). 
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Figure 12. Open Field Test in untreated C57BL/6J adolescent and old mice. Parameters: A: Distance travelled [m], B: 
Rearing number and C: Resting time [s] measured in an Open Field apparatus for 10 min in the darkness (infrared). 
Means ± SEM from 8 mice. Student’s t-test: ***p<0.001. 
 
Acute treatment with Δ9-THC suppressed activity also in old mice; the % activity suppression 
tended to be higher in old vs. adolescent mice for each of the three parameters (Figure 13). 
Chronic treatment led to a suppressed activity also in old mice; again, the activity suppression 
tended to be higher in old than in adolescent mice (Figure 13). The % activity suppression was 
lower for each of the three parameters after chronic than acute administration of Δ9-THC, both 
in adolescent and old animals; however, this difference reached significance for the rearing 
number in adolescent animals only (Figure 13). Ageing does not alter tolerance development in 
the rearing number and resting time, i.e., activity suppression was attenuated by 40-50 % when 
compared to acute treatment (Figure 13B, C, Table 15). With respect to the distance travelled, 
tolerance development appears to be lower in old (by 21 %) than in adolescent mice (by 46 %); 
the difference does, however, not reach a significant level (Figure 13A, Table 15). 
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Figure 13. Open Field Test in Δ9-THC treated C57BL/6J adolescent and old wild type mice. Parameters measured: A: 
distance travelled, B: rearing number and C: resting time, normalized and expressed in percent of activity 
suppression. Treatment groups: Acute – pre-treated with vehicle and challenged with 10 mg/kg Δ9-THC, Chronic – 
pre-treated and challenged with 10 mg/kg Δ9-THC. Means ± SEM from 7-9 mice. Student’s t-test: *p<0.05. 
 
Tolerance [%] 
Distance travelled Rearing number Resting time 
Adolescent 46 45 50 
Old 21 44 39 
Table 15. Comparison of tolerance development towards Δ9-THC in adolescent and old mice for the three parameters 
of the Open Field Test. Tolerance (%) was calculated as    
                              
                            
      . 
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1.2 Biochemical test: 35S-GTPS binding 
1.2.1 General 
To optimize the agonist-stimulated 35S-GTPS binding method for experiments on 
pharmacologically treated mice, numerous pre-tests were conducted to find an appropriate CB1 
receptor agonist. 
One of the most potent synthetic CB1 receptor agonists, WIN 55,212-2 (Griffin et al. 1998; 
Pertwee and Ross 2002; Childers 2006; Svízenská et al. 2008, described in section A.2.1.1; for 
structure see Table 2), was used in 35S-GTPS binding studies on wild type (CB1+/+) mouse 
hippocampal membranes. As shown in Figure 14, WIN 55,212-2 concentration-dependently 
stimulated specific 35S-GTPS binding; an increase of specific binding by 156 % was observed at 
30 µM WIN 55,212-2, the highest concentration tested. 
 
 
Figure 14. Effect of the CB1 receptor agonist WIN 55,212-2 on the specific 35S-GTPS binding to C57BL/6J wild type 
mouse hippocampus membranes (6.5 µg/50 µl). Means ± SEM from 7 experiments. Unspecific binding (in the 
presence of GTPS 10 µM): 27± 1 %. 
 
Several references point to unspecific, non-cannabinoid receptor dependent effects of  
WIN 55,212-2 (Breivogel et al. 2001; Wiley and Martin 2002). To investigate whether this is 
relevant for the present experiments on hippocampus membranes, 35S-GTPS binding 
experiments were carried out on hippocampal membranes from CB1 receptor knockout mice 
(CB1-/-). Since in hippocampal membranes from CB1 receptor deficient mice WIN 55,212-2,  
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30 µM still increased binding by 43 %, (Figure 15) we were wondering whether this effect is 
related to CB2 receptor activation. Since the expression of the CB2 receptor in the central 
nervous system remains a controversial issue (Griffin et al. 1999; Gong et al. 2006; Atwood and 
Mackie 2010), further experiments on CB1 and CB2 double knockout mice  
(CB1-/-/CB2-/-) were conducted. As shown in Figure 15, the concentration-response curves of  
WIN 55,212-2 in membranes from CB1-/- and CB1-/-/CB2-/- mice were virtually identical. Again, an 
increase in specific binding by 43 % occurred at 30 µM. These findings indicate that the effects 
obtained with WIN 55,212-2 are related to an unknown, CB1 and CB2 receptor-independent 
mechanism. 
 
 
Figure 15. Effect of the CB1 receptor agonist WIN 55,212-2 on the specific 35S-GTPS binding to C57BL/6J wild type 
(CB1+/+), CB1 receptor knockout (CB1-/-) and CB1 and CB2 receptor double knockout (CB1-/-/CB2-/-) mouse brain 
hippocampus membranes (6.5 µg/50 µl). Means ± SEM from 3-7 experiments. Unspecific binding (in the presence of 
GTPS 10 µM): 29 ± 2 %. 
As already mentioned, the maximum effect of 156 % was decreased to 43 % in CB1-/- and double 
knockout mice (Figure 15, Table 16). Moreover, the potency of WIN 55,212-2, expressed as the 
pEC50 value, was reduced by a factor of ~ 25 in membranes from knockout and double knockout 
mice (Table 16). 
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Mouse strain pEC50 value Maximal binding [%] 
Wild type (CB1+/+) 6.87 ± 0.12 156 ± 7 
CB1 knockout (CB1-/-) 5.43 ± 0.20 *** 43 ± 3 *** 
CB1 and CB2 double knockout (CB1-/-/ CB2-/-) 5.45 ± 0.34 ** 43 ± 8 *** 
Table 16. pEC50 values and maximal effects of WIN 55,212-2 for 35S-GTPS binding studies on wild type (CB1+/+), CB1 
receptor knockout (CB1-/-) and CB1 and CB2 receptor double knockout (CB1-/-/ CB2-/-) mice. The maximal binding of 
WIN 55,212-2 occurred at 30 µM. Means ± SEM from 3-7 experiments. One-way ANOVA with Bonferroni’s multiple 
comparison test: **p<0.01, ***p<0.001. 
The WIN 55,212-2-related increase in 35S-GTPS binding on membranes from CB1 and CB2 
knockout mice (see Figure 15) speaks against the use of WIN 55,212-2 as an appropriate agonist 
for further experiments. Therefore, another potent cannabinoid receptor agonist, CP 55,940 (for 
structure see Table 2), was studied on membranes from wild type (CB1+/+) and CB1 receptor 
deficient mice (CB1-/-). 
As shown in Figure 16 and summarized in Table 17, CP 55,940 stimulated specific 35S-GTPS 
binding concentration-dependently; the maximum, obtained at a concentration of 30 µM, was  
94 %. The same dilution series of CP 55,940 examined on hippocampal membranes from CB1 
receptor knockout mice (CB1-/-) failed to alter specific 35S-GTPS binding. Thus, further 
experiments on membranes from CB1 and CB2 double knockout mice were not necessary. 
 
Figure 16. Effect of the CB1 receptor agonist CP 55,940 on the specific 35S-GTPS binding on C57BL/6J wild type 
(CB1+/+), and CB1 knockout (CB1-/-) mouse brain hippocampus membranes (6.5 µg/50 µl). Means ± SEM from 3-4 
experiments. Unspecific binding (in the presence of GTPS 10 µM): 26 ± 4 %.  
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Although the WIN 55,212-2-stimulated 35S-GTPS binding on wild type mouse hippocampus was 
stronger (maximal binding of 156%) than that of CP 55,950 (maximal binding of 94%), as shown 
in Table 17, the absence of a non-specific effect of CP 55,940 in CB1 receptor knockout mice  
(CB1-/-) provides a sufficient reason to choose CP 55,940 as a standard agonist for further 
investigation of CB1 receptor activity changes. Interesting enough, the potency (pEC50) of  
CP 55,940 is 2.8-fold higher than that of WIN 55,212-2 (Table 17 and Table 16). 
 
Mouse type pEC50 value Maximal binding [%] 
Wild type (CB1+/+) 7.32 ± 0.24 94 ± 7 
CB1 knockout (CB1-/-) - -2 ± 6 *** 
Table 17. pEC50 value in wild type mice and maximal binding effects of CP 55,940 in wild type (CB1+/+) and CB1 
receptor knockout (CB1-/-) mice in 35S-GTPS binding studies. The maximal binding effect obtained with CP 55,940 
occurred at of 30 µM. Means ± SEM from 3-4 experiments. Student’s t test: ***p<0.001. 
 
1.2.2 Comparison of adolescent and old mice 
The 35S-GTPS binding studies on mouse hippocampal membranes were conducted to 
investigate the activity of the CB1 receptor after chronic Δ9-THC treatment. For this purpose, the 
hippocampi of the mice repetitively treated with 9-THC and their vehicle treated, age-matched 
controls were examined to detect adaptive receptor changes in 35S-GTPS binding experiments. 
The adolescent and old mice pre-treated according to the scheme in Table 7 and tested in the 
Open Field Test were subsequently killed by decapitation; brains were removed and hippocampi 
isolated as described in section B.2.3.2. All 35S-GTPS binding experiments in this series were 
evaluated using “cpm over basal” values as the unit of the CB1 receptor activation. The use of  
“% of controls” was inappropriate for presentation of this data, since surprisingly there were 
differences between the groups at the level of basal receptor binding (receptor binding in the 
absence of any agonist, see Figure 17). The unspecific binding was between 15 and 26 % of total 
binding. 
As shown in Figure 17, basal 35S-GTPS binding of adolescent mice chronically treated with  
9-THC was significantly lower than basal binding of vehicle-treated age-matched mice. In other 
words, the basal binding of chronically 9-THC treated adolescent mice was down-regulated. 
Basal binding to hippocampi of chronically 9-THC and vehicle treated aged mice did not differ; 
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these values did not differ from basal binding of adolescent 9-THC treated mice, but were lower 
than basal binding of adolescent vehicle treated mice. 
 
 
Figure 17. Basal 35S-GTPS binding (cpm) to adolescent and aged C57BL/6J wild type mouse hippocampal membranes 
(6.5 µg/50 µl). Vehicle – mice pre-treated and challenged with vehicle; Chronic – mice pre-treated and challenged 
with 10 mg/kg Δ9-THC. Means ± SEM from 7-9 experiments. Unspecific binding (in the presence of GTPS 10 µM):  
13.3 ± 1.8 % (adolescent) and 17 ± 0.4 % (old). One-way ANOVA with Tukey multiple comparison post-test: *p<0.05, 
**p<0.01, ***p<0.001. 
 
The concentration-response curves of the CP 55,940-induced 35S-GTPS binding in adolescent 
mice (Figure 18A) strongly differed for membranes from 9-THC and vehicle treated mice 
(significant difference for CP 55,940  0.03 µM). Membranes from 9-THC treated young animals 
showed a lower receptor binding, compared to vehicle treated mice. On the other hand, as 
shown in Figure 18B, chronic treatment with 9-THC did not affect the concentration-response 
curves of CP 55,940-induced 35S-GTPS binding within the aged mice. 
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Figure 18. Effect of the CB1 receptor agonist CP 55,940 on the 35S-GTPS binding (cpm over basal) to hippocampal 
membranes from adolescent (A) and old (B) C57BL/6J wild type mice (6.5 µg/50 µl). Vehicle – animals pre-treated 
and challenged with vehicle only; Chronic – pre-treated and challenged with 10 mg/kg Δ9-THC. Means ± SEM from 7-8 
(A) and 9 (B) experiments. Unspecific binding (in the presence of GTPS 10 µM): 13.3 ± 1.8 % (A) and 17 ± 0.4 % (B). 
Student’s t-test: *p<0.05, **p<0.01. 
 
As shown in Figure 19 and Table 18, the maximal binding (binding stimulated by CP 55,940 at a 
concentration of 30 µM) was significantly down-regulated in adolescent, 9-THC treated mice 
compared to their vehicle treated controls. In aged animals no significant differences in maximal 
binding occurred between the two treatment groups. The potency of CP 55,940 was identical for 
each of the four groups of animals (Table 18). 
 
Treatment Age pEC50 value Maximal binding [cpm over basal] 
Vehicle (control) 
Adolescent 
7.48 ± 0.19 2440 ± 300 
Δ9-THC 10 mg/kg (chronic) 7.38 ± 0.15 1440 ± 130 
Vehicle (control) 
Old 
7.49 ± 0.15 1030 ± 90 
Δ9-THC 10 mg/kg (chronic) 7.46 ± 0.19 1020 ± 110 
Table 18. Maximal binding (obtained with 30 µM CP 55,940) and pEC50 values of the CP 55,940-stimulated 35S-GTPS 
binding in hippocampal membranes from vehicle and Δ9-THC chronically treated adolescent and old C57BL/6J wild 
type mice. Vehicle – animals pre-treated and challenged with vehicle only, Chronic – pre-treated and challenged with 
10 mg/kg Δ9-THC. Means ± SEM from 7-9 experiments. 
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Figure 19. Maximal effect of the CB1 receptor agonist CP 55, 940 for its stimulatory effect on 35S-GTPS binding (cpm 
over basal) to hippocampal membranes from adolescent and old C57BL/6J wild type mice (6.5 µg/50 µl).  
Vehicle – animals pre-treated and challenged with vehicle only; Chronic – pre-treated and challenged with 10 mg/kg 
Δ9-THC. Means ± SEM from 7-9 experiments. Unspecific binding (in the presence of GTPS 10 µM): 13.3 ± 1.8 % 
(adolescent) and 17 ± 0.4 % (old). One-way ANOVA with Tukey multiple comparison post-test: **p<0.01, ***p<0.001. 
 
2. Effect of MAGL blockade on CB1  receptors 
It was reported in the literature that endogenous and exogenous cannabinoids can act 
neuroprotective (Centonze et al. 2007; Bilkei-Gorzo 2012). Activation of CB1 receptors protects 
against age-related neuronal damage (Albayram et al. 2011; 2012), but on the other hand, long-
term CB1 receptor activation can lead to adaptive changes and receptor down-regulation, as 
shown in this thesis in adolescent mice chronically treated with 9-THC and in numerous other 
reports (Martin et al. 2004). The indirect activation of the endocannabinoid system through 
degradation blockade as therapeutic target is attracting more and more attention (Di Marzo et 
al. 2007; Fowler 2012; Katz et al. 2014). 
The goal of this part of the project was to find a JZL 184 dose and treatment period which 
enhance endocannabinoid levels, but do not elicit receptor down-regulation in mouse 
hippocampus. Briefly, the levels of the endocannabinoids (2-AG and AEA) and of their 
degradation product (AA) were determined and correlated with receptor activity changes. 
In detail, male CD 1 mice were treated with JZL 184 once daily in doses of 4, 10 and 40 mg/kg or 
with vehicle during different periods of time (1 day, 3 days and 14 days), according to the 
scheme presented in Table 8. About 24 h after last treatment, animals were killed by 
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decapitation and each hemisphere of the hippocampus was isolated separately and rapidly 
frozen in pre-cooled reaction tubes. The left hemisphere of the hippocampus was used for  
35S-GTPS binding studies whereas the right hemisphere was stored for endocannabinoid 
determination with the LC-MS/MS (LC-MRM) method. 
 
2.1 Endocannabinoids determined by LC-MRM 
As described in section A.2.1.2 and presented in Figure 5 and Figure 6, both main 
endocannabinoids AEA and 2-AG are hydrolysed by specific degrading enzymes. Although 
different enzymes are involved in the degradation of each endocannabinoid (FAAH for AEA and 
MAGL for 2-AG), one of the products of the hydrolysis reaction, namely arachidonic acid, is the 
same for both substrates.  
As presented in Figure 20A, after a single dose of JZL 184 (treatment duration of 1 day), only the 
highest dose of 40 mg/kg JZL 184 caused a significant elevation in 2-AG concentration whereas 
both lower JZL 184 doses (4 and 10 mg/kg) failed to do so. After 3 days of treatment, the 2-AG 
level was still significantly affected only by 40 mg/kg JZL 184, however, the JZL 184 dose of  
10 mg/kg tended to increase the 2-AG concentration. The chronic treatment with JZL 184 for  
14 days resulted in a strong, significant increase in the 2-AG concentration at 10 and 40 mg/kg 
whereas 4 mg/kg JZL 184 did not affect the 2-AG level. Furthermore, after 14 days of JZL 184 
administration, the AA concentrations were affected in the opposite way compared to the 2-AG 
levels (see Figure 20C). Since the AA is formed as one of the products of endocannabinoid 
degradation (see Figure 5 and Figure 6), JZL 184 at 40 mg/kg and surprisingly 4 mg/kg but not 
at 10 mg/kg given for 14 days was associated with AA concentrations significantly lower than 
control. The AEA concentrations were not affected by any dose of JZL 184, even after long-term 
treatment (Figure 20B). 
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Figure 20. Concentrations of the endocannabinoids 2-AG and AEA and their degradation product AA in the 
hippocampus of JZL 184 treated CD-1 mice. 2-AG [nmol/g] levels after 1, 3 and 14 days of JZL 184 or vehicle 
treatment; AEA [pmol/g] and AA [nmol/g] after 14 days of JZL 184 or vehicle treatment. Means ± SEM from 7-8 mouse 
hippocampi. One-way ANOVA with Bonferroni multiple comparison post-test: *p<0.05, **p<0.01, ***p<0.001. 
 
To sum up, the dose of 40 mg/kg JZL 184 was the most effective one and caused a significant 
elevation of the 2-AG concentration from the first day of administration onward, whereas  
4 mg/kg JZL 184 failed to affect the 2-AG concentration regardless of the treatment duration. 
The dose of 10 mg/kg caused a significant increase in 2-AG level after 14 days of JZL 184 
administration, but an upward trend was visible already after 3 days of administration. 
 
2.2 CB1 receptor activity determined by 35S-GTPS binding 
As described in section A.2.1.2, the treatment with JZL 184 causes MAGL blockade and thus 
inhibition of the 2-AG metabolism. The elevated concentration of 2-AG causes enhanced 
cannabinoid receptor activation. The long-term activation of a given receptor can result in its 
desensitization and/or down-regulation (Martin et al. 2004). Studying the CP 55,940-stimulated 
35S-GTPS binding, the functional changes of the CB1 receptor through JZL 184 (administrated at 
different doses and over different time periods) were examined. 
Basal 35S-GTPS binding, which was 947 ± 224 cpm in membranes from vehicle-treated mice 
(mean value ± SEM; n=6) was not affected by the JZL 184 treatment (not shown). As shown in 
Figure 21, the CP 55,940-stimulated 35S-GTPS binding to the hippocampus of mice treated with 
4, 10 and 40 mg/kg JZL 184 and vehicle for 14 days did not differ significantly between 
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treatments. The concentration-response curves of the animals treated with 4 and 10 mg/kg  
JZL 184 coincided with the curve of the vehicle-control. However, the curve for the mice treated 
with 40 mg/kg JZL 184 showed a tendency (not significant) towards a down-regulation of the 
specific binding, compared to the control. 
 
 
Figure 21. Effect of the CB1 receptor agonist CP 55,940 on the specific 35S-GTPS binding (cpm over basal) to 
hippocampal membranes from CD-1 mice (6.5 µg/50 µl). Concentration-response curves of animals treated for  
14 days with 4, 10 or 40 mg/kg JZL 184 or with vehicle. Means ± SEM from 5-6 experiments. Unspecific binding (in the 
presence of GTPS 10 µM): 12.2 ± 0.8 % 
 
The concentration-response curves for 35S-GTPS binding to hippocampal membranes did not 
differ between treatment regimens when JZL 184 at any dose was given for 1 day or 3 days only; 
therefore, the corresponding concentration-response curves are not shown here. 
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3. Searching for H4  receptors 
The presence of the H4 receptor in the CNS has been a controversial topic for over one decade 
(Liu et al. 2001; Strakhova et al. 2009; reviewed by Marson 2011). In this thesis, I studied the 
mRNA expression of the H4 receptor in guinea pig cerebral cortex and sought for a functional 
readout of this receptor in the CNS using the 35S-GTPS binding method. 
 
3.1 Searching for mRNA: RT-PCR 
Male Dunkin‐Hartley guinea pigs were killed by decapitation and the cerebral cortex and spleen 
were isolated and directly frozen at -80 C. Further procedures, such as tissue preparation, 
genetic material isolation, PCR and agarose gel electrophoresis were conducted as described in 
section: B.2.5. Primer sequences used for the PCR experiments are listed in Table 12. 
The presence of H4 receptor mRNA was previously detected in human and mouse cerebral 
cortex using the RT-PCR method (Schulte 2011). Therefore, detection of the H4 receptor in the 
cortex tissue of the guinea pig was tried as well. The guinea pig spleen was examined for 
comparison, since it is well known that the H4 receptor is expressed in this organ  
(Liu et al. 2001). 
Figure 22 shows that the 344 bp products expected for the H4 receptor sequence were found in 
cerebral cortex and spleen (positive control) of the guinea pig. The 567 bp GAPDH product 
(housekeeping gene) was also shown for both tested tissues. 
 
Figure 22. Detection of histamine H4 receptor mRNA in the guinea-pig cerebral cortex and spleen by reverse 
transcriptase-polymerase chain reaction. The arrows in the upper panels (H4) indicate the products expected for the 
guinea-pig H4 sequence, whereas the arrows in the lower panels (GAPDH) refer to GAPDH, which was used as a 
housekeeping gene. Water was used instead of cDNA template as a negative control. The scale for the molecular 
weights of the amplicons (expressed in base pairs, bp) is given on the left of each panel (Marker). Representative 
picture chosen from n=3 experiments. 
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3.2 Searching for a functional readout: 35S-GTPS binding 
To investigate the presence of functional histamine H4 receptor on membranes of cerebral 
cortex of guinea pig and mouse, 35S-GTPS binding was studied in cortex homogenates.  
4-Methylhistamine was chosen as H4 receptor agonist. The H3 agonist R-α-methylhistamine 
served as positive control to verify the functionality of the assay (for chemical structures of the 
histamine receptor ligands see Table 4). 
On guinea pig cerebral membranes (Figure 23A), 4-methylhistamine did not have any effect up 
to 1 µM. Nevertheless, a further increase of the 4-methylhistamine concentration enhanced the 
35S-GTPS binding (by 13 % at 100 µM). The addition of the H4 receptor antagonist JNJ-7777120 
in a concentration of 1 µM did not alter the effect of 4-methylhistamine on guinea pig cerebral 
cortex membranes. JNJ-7777120 1 µM, given alone, did not show any effect on 35S-GTPS binding 
in guinea pig cortex. The partial agonist of the H4 receptor, ST-1006, also failed to cause any 
effect on the 35S-GTPS receptor binding, even at a concentration as high as 100 µM. The positive 
control is presented in Figure 23B. The H3 receptor agonist R-α-methylhistamine 0.001 to 0.3 µM 
concentration-dependently enhanced 35S-GTPS binding with a maximal binding effect of 23 % 
which was induced by 0.1 µM R-α-methylhistamine. The addition of the H3 receptor antagonist 
thioperamide at 0.1 µM caused a rightward-shift of the R-α-methylhistamine curve, which 
confirms the involvement of the H3 receptor. Thioperamide, given alone (0.1 µM), did not affect 
the specific 35S-GTPS binding. 
 
Figure 23. Effect of histamine H4 (A) and H3 (B) receptor ligands on the specific 35S-GTPγS binding to guinea pig cortex 
membranes. The effect of (A) the H4 agonist 4-methylhistamine, the partial H4 agonist ST-1006, the H4 antagonist JNJ-
7777120 and (B) the H3 agonist R--methylhistamine and the H3 antagonist thioperamide (as positive controls) were 
studied. H4 and H3 receptor ligands were given alone or combined. Means ± SEM from 3 - 6 experiments. Unspecific 
binding (in the presence of GTPS 10 µM): 22.3± 0.8 (A) and 13.3 ± 1.3 (B). 
Results 
65 
In experiments on mouse cortical membranes (C57BL/6J, wild type), 4-methylhistamine 3 nM to 
30 µM failed to stimulate the specific 35S-GTPγS binding (Figure 24A), whereas the H3 receptor 
agonist R-α-methylhistamine caused a 23 % increase in 35S-GTPγS binding (Figure 24B). The 
addition of 0.1 µM thioperamide resulted in the shift of the R-α-methylhistamine curve to the 
right, as expected. Thioperamide given alone failed to affect the binding (Figure 24B). 
 
Figure 24. Effect of histamine H4 (A) and H3 (B) receptor ligands on the specific 35S-GTPγS binding to C57BL/6J mouse 
cortex membranes. The effect of (A) the H4 agonist 4-methylhistamine and (B) the H3 agonist  
R--methylhistamine and the H3 antagonist thioperamide (as positive control) were studied. The H3 receptor ligands 
were given alone or combined. Means ± SEM of 3 - 6 experiments. Unspecific binding (in the presence of GTPS  
10 µM): 26.2± 2.8 (A) and 24.7 ± 0.7 (B). 
 
The agonistic potency of R-α-methylhistamine (expressed as pEC50) and the antagonistic 
potency of thioperamide (expressed as pA2) are given in Table 19. The values for either ligand 
are virtually identical for guinea pig and mouse. 
 
Ligand Potency estimate Guinea pig Mouse (C57BL/6J) 
R-α-methylhistamine pEC50 8.3 8.4 
Thioperamide pA2 8.2 8.5 
Table 19. Potencies of the H3 receptor agonist R-α-methylhistamine and the H3 receptor antagonist thioperamide in 
the 35S-GTPγS binding assay in guinea pig and mouse hippocampal membranes. Values are based on the 
concentration-response curves in Figure 23B (guinea pig) and Figure 24B (mouse). 
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D. Discussion 
1. Effects of 9-THC on CB1 receptors 
The development of tolerance to 10 mg/kg 9-THC was examined in two age groups of mice, 
adolescent and old, and the influence of aging on animal behaviour was compared with 
functional changes of CB1 receptors in hippocampal membranes. Note that in this section the 
term “9-THC“ corresponds to the dose of 10 mg/kg 9-THC. 
 
1.1 Behavioural test: Open Field Test 
The analysis of behavioural tests is difficult because of the low reproducibility of the results 
between single experiments even in the same laboratory; comparisons between different 
laboratories are almost impossible. Numerous factors can affect the behaviour of an animal. 
Stress, which is strongly modulated by environmental factors, plays an indisputable role in 
behavioural experiments. Housing conditions, such as group or individual housing, long-term or 
short-term housing, the temperature, noise, light (Jähkel et al. 2000; Turner et al. 2005; Obernier 
and Baldwin 2006; Gonder and Laber 2007), human-animal interactions and pain have to be 
considered (Würbel 2002). All these exogenous factors as well as the individual health condition 
and individual activity of the mouse can affect the behaviour. In the Open Field Test procedure, 
each movement of the experimenter can increase the anxiety of the mice and thus influence their 
performance in the test. 
 
1.1.1 General 
The activity of 9-THC was described in this thesis in section A.1. Briefly, 9-THC interacts as a 
partial agonist with both cannabinoid receptors, CB1 and CB2, which are expressed in numerous 
tissues and organs in mammalian organisms. This interaction is responsible for the broad and 
complex effects of cannabinoids in animals and humans (Pertwee et al. 2010). Accordingly, a 
variety of models has been developed; moreover, the development of tolerance to 9-THC was 
studied in rodents and other species as reviewed by González et al. (2005). The differential 
protocols to produce tolerance to 9-THC provide numerous variables, which complicate the 
comparison of these studies and provide unclear and sometimes contradictory results. The 
ambiguity of the results can be related to the route of drug administration, the 9-THC dose and 
the treatment duration. In addition, the tests used, the time between drug administration and 
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test conduction, experimental conditions, such as light, animal handling or acclimatization 
period and at last the way of data analysis influence the final results. These and other aspects 
will be discussed in this section. 
The protocol used in this study to induce 9-THC tolerance was based on that published by Bass 
and Martin (2000). They established the time course for the induction of 9-THC tolerance in 
behavioural tests of antinociception (reduced pain sensitivity) and hypoactivity (suppression of 
spontaneous activity). Under numerous doses and treatment periods they tested, the regimen of 
seven single doses of 10 mg/kg 9-THC twice a day (3.5 days of treatment) caused the strongest 
decrease in the potency of the challenge dose of 10 mg/kg 9-THC in mice. In this thesis, I 
compared tolerance development between two age groups: adolescent (6 weeks) and old (12 
months). 
The main modifications adopted in our experiments, compared to the protocol of Bass and 
Martin (2000), are summarized in Table 20. Bass and Martin (2000) used ICR mice, as opposed 
to C57BL/6J mice used in this study. As reported in the literature (Hotchkiss et al. 2004; 
Daskalakis et al. 2014) differences in response between mouse strains are possible, however, the 
cited references correspond to different experimental parameters. The routes of administration 
of the drug or vehicle differed as well, as described in Table 20. To induce tolerance, 9-THC was 
administered i.p. (Bass and Martin 2000: s.c.); the challenge dose of 9-THC was again 
administered i.p. (Bass and Martin 2000: i.v.). 
I.p. injections were chosen for the present experiments since they represent a common and quite 
simple laboratory technique of drug administration. However, a lower accuracy of 
administration may be associated with i.p. injections. The fluid may be erroneously injected into 
the urinary bladder, gastrointestinal tract or subcutaneously (Turner et al. 2011). Furthermore, 
after i.p. administration, a delay of the effect occurs, what I compensated for by a longer time 
interval between the injection of the 9-THC challenge dose and the Open Field Test procedure 
(40 min after i.p. injection instead of 5 min after i.v. injection). 
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 Bass and Martin (2000) This thesis 
Mouse strain ICR C57BL/6J 
Treatment groups 
I. Chronic 
II. Acute 
III. Vehicle (control) 
I. Chronic 
II. Acute 
III. Vehicle (control) 
Age groups No age groups 
I. Adolescent (6 weeks) 
II. Old (12 months) 
Induction 
of 
tolerance 
Dose of 9-THC 10 mg/kg and other doses 
(3 mg/kg, no effect) 
10 mg/kg 
Route of 
administration 
s.c. i.p. 
Challenge 
dose 
Dose of 9-THC 10 mg/kg 10 mg/kg 
Route of 
administration 
i.v. in the tail vain i.p. 
Time interval between 9-THC 
challenge dose and OFT 
5 min 40 min 
Behavioural test 
Spontaneous activity in the 
Animal Activity Monitor 
Distance travelled, rearing 
number and resting time in 
the Open Field Test using 
the ActiMot Software 
Table 20. Differences between the protocols used by Bass and Martin (2000) and in this thesis. i.p. - intraperitoneal; 
i.v. - intravenous; s.c. – subcutaneous. 
 
The way of analysis and presentation of the data is a key for understanding the changes between 
the tested groups. The “raw” data of the three parameters tested in the Open Field Test either 
represent activity of the mice (distance travelled and rearing behaviour) or suppression of the 
activity (resting time). To simplify the analysis and to standardize the data presentation, 
parameters were expressed as percentage values of activity suppression (% activity 
suppression; calculation method described in section B.2.2). 
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1.1.2 Comparison of adolescent and old mice 
Three questions were considered. First, does aging influence the basal activity of the animals? 
The three parameters were affected differently (Figure 12). Although the rearing number (which 
is related to the exploratory behaviour of the mouse) decreased with age, the other parameters 
(distance travelled and resting time) did not show age-related differences. Second, does 
repeated administration of 9-THC induce tolerance? Figure 13 shows that repeated injection of 
9-THC reduced the activity suppression elicited by a challenge dose of 9-THC by ~ 20 – 50 %; 
the difference, however, reached significance for one of the 6 groups only, namely for the rearing 
number in the adolescent group. Third, is the development of tolerance age-dependent?  
A comparison of the three behavioural paradigms shows that the tolerance development does 
not show an age-dependent decline for the rearing number and the resting time (Figure 13, 
Table 15). With respect to the distance travelled, one might assume that the tolerance is marked 
in the adolescent but only slight in the old animals; however, the values are not significantly 
different. 
Although greater behavioural effects were expected based on the data published by Bass and 
Martin (2000), the trends presented in the behavioural tests in this thesis confirm the current 
state of knowledge about the 9-THC tolerance development. 
 
1.2 Biochemical test: 35S-GTPγS binding 
1.2.1 General 
An unspecific effect of WIN 55,212-2 on 35S-GTPγS binding to hippocampal membranes from CB1 
knockout mice (CB1-/-) was shown by Breivogel et al. (2001). Moreover, such an unspecific effect 
was also found in other experimental methods (reviewed by Wiley and Martin 2002). Therefore, 
in this thesis, the effect of WIN 55,212-2 on 35S-GTPγS binding was tested for CB1 knockout  
(CB1-/-) and CB1 and CB2 receptor double knockout (CB1-/-/CB2-/-) mice. An identical unspecific 
binding was found in hippocampal membranes from both mice strains (Figure 15). Due to this 
finding, the cannabinoid receptor agonist CP 55,940, which by itself failed to activate 35S-GTPγS 
binding on CB1 knockout (CB1-/-) mice (Figure 16), was chosen as an appropriate agonist for 
further 35S-GTPγS binding experiments. 
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1.2.2 Comparison of adolescent and old mice 
In each 35S-GTPγS binding experiment, the basal binding was measured in the absence of any 
exogenous agonist and for later data evaluation (the use of the basal binding values in data 
evaluation is described in section B.2.3.2; Equation 4 – 6). The basal binding value represents  
the activity of GPCRs expressed and acting spontaneously and/or interacting with their 
endogenous ligands in the tested tissue (here in the hippocampus), e.g. CB1, opioid, dopamine or 
adenosine receptors (Marchese et al. 1999) and many more. The CB1 receptors which are 
extremely highly expressed GPCRs in the CNS (Herkenham et al. 1991; Tsou et al. 1998) have a 
dominant impact on the basal binding value. As described in section B.2.3.2, the incubation of 
the hippocampus tissue homogenates with ADA serves to improve the basal binding signal 
through deactivation of the endogenously formed adenosine, thereby improving the detection of 
the agonist-induced CB1 receptor binding. 
As presented in Figure 17, the basal binding of vehicle treated adolescent mice was much higher 
than that of the vehicle treated old animals. As a matter of fact, the basal activity seems to 
decrease with age, e.g. due to a lower density and/or spontaneous activity of CB1 receptors. 
Basal binding was also influenced differently in hippocampal membranes from adolescent and 
aged mice by 9-THC treatment. Although a down-regulation occurred in adolescent animals, no 
difference was obtained for aged mice. Those data may mean that the receptor density and/or 
spontaneous activity of CB1 receptors is no longer susceptible to adaptive changes in aged 
animals. 
The comparison of the CP 55,940-induced 35S-GTPγS binding provided conclusions analogous to 
those reached for basal binding. As shown in Figure 18A, significant differences between the 
concentration-response curves occurred within the adolescent group. The hippocampal CB1 
receptor activity in adolescent animals pre-treated with 9-THC was significantly decreased, 
compared to the age-matched vehicle treated controls (Figure 18A), indicating down-regulation 
of the CB1 receptors through the long-term 9-THC pre-treatment. On the other hand, as shown 
in Figure 18B, no differences in specific 35S-GTPγS binding between treatments were observed 
within the old age group. 
One finding, namely the decrease in basal 35S-GTPγS binding after pre-treatment with 9-THC in 
adolescent mice, has, to the best of my knowledge, not been reported previously and interferes 
with the interpretation of the data. Thus, one may argue that the decrease in the CP 55,940-
induced 35S-GTPγS binding after 9-THC pre-treatment is solely due to the fact that basal binding 
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was lowered in parallel. To overcome this problem, additional experiments would be interesting 
in which an agonist facilitating 35S-GTPγS binding via a non-CB1 receptor is studied. If the 
maximum signal of such an agonist is unaffected by 9-THC pre-treatment, this would lend 
further support to our view that CB1 receptor activity and/or density is decreased. If, however, 
the maximum signal of the reference agonist is decreased as well, one has to be cautions with 
postulating a tolerance development of CB1 receptors. 
The question arises whether behavioural and binding data can be correlated. The age-related 
decline in rearing behaviour might be indeed correlated with the decrease in basal binding. On 
the other hand, the possibility has to be considered that the same direction of both parameters is 
an accidental event. Moreover, the other two behavioural paradigms (distance travelled; resting 
time) did not show an age-dependent alteration. 
 
If one compares the CP 55,940-induced increase in 35S-GTPγS binding and the alteration of 
behavioural parameters by a challenge dose of 9-THC, the results are again only partially 
congruent. In adolescent animals, both binding and behaviour showed a tolerance after 9-THC 
pre-treatment. If one, however, considers aged animals, behaviour shows tolerance 
development whereas binding fails to do so after repeated administration of 9-THC. With 
respect to one behavioural parameter, distance travelled, the tolerance development in response 
to 9-THC pre-treatment tended to be (but was not significantly) less marked in aged than in 
adolescent mice. 
 
The discrepancy between behavioural effects and 35S-GTPγS receptor binding could be among 
others due to the factors discussed in paragraph D.1.1 in this section. A longer treatment period 
should be chosen in the future to test if the behavioural tolerance increases with treatment 
duration. It would be interesting to investigate also other brain regions for 35S-GTPγS receptor 
binding changes after 9-THC chronic treatment. Furthermore, the investigation of additional 
age groups could provide more exact information with respect to the time-point at which 
receptor adaptation due to the 9-THC chronic administration ceases to occur. 
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2. Effect of MAGL blockade on CB1  receptors 
CB1 receptor have a protective effect against some age-dependent alterations in the brain 
(Albayram et al. 2011; 2012; Bilkei-Gorzo et al. 2012; Bilkei-Gorzo 2012) and the possibility has 
to be considered that drugs activating CB1 receptors may be beneficial against the age-related 
decline in brain function. Although 9-THC is not suited for this purpose due to its addictive 
properties, a compound like JZL 184, that inhibits the degradation of the endogenously formed 
cannabinoid 2-AG via MAGL, may be interesting and indeed beneficial effects of MAGL blockade 
have been shown in neurodegenerative diseases (Chen et al. 2012). The major challenge of such 
an approach is to find a treatment schedule under which endogenous 2-AG levels are increased 
but a concomitant down-regulation of CB1 receptors is lacking (or weak). A high dose of JZL 184 
(daily i.p. injections of 40 mg/kg over a time period of 6 days) indeed did not only increase 2-AG 
levels but also decreased the CB1 receptor-mediated 35S-GTPγS binding in the mouse brain 
(Schlosburg et al. 2010). In the present study, lower doses of JZL 184 than 40 mg/kg and an 
acute, subacute (3 days) and chronic (14 days) treatment schedule of this drug were examined 
(Table 21). This part of the study was restricted to adolescent mice since, as shown in the first 
part (C.1.2), CB1 receptor-dependent alterations did not occur in binding studies on hippocampal 
membranes from aged animals. 
For this purpose, endocannabinoid levels were determined in the hippocampi of the mice 
treated with JZL 184 using LC-MS/MS tandem mass spectrometry (LC-MRM). Furthermore, CP 
55,940-stimulated 35S-GTPγS binding was determined in the hippocampi of the treated mice to 
investigate the receptor activity changes caused by MAGL blockade. The CD-1 (and not the 
C57BL/6J) mouse strain was chosen. According to the mouse growth charts published on the 
website of the mouse provider company Charles Rivers (http://www.criver.com), the weight of 
the 6 week old male CD-1 mouse is 30 – 35 g whereas the age-matched C57BL/6J mouse weighs 
20 – 25 g only. Since endocannabinoid level measurement and 35S-GTPγS binding were 
conducted each on the opposite hippocampus hemispheres of the same mouse, extensive 
amounts of tissue were needed. The weight of the mouse and hence the expected larger brain 
size was crucial for planning of experiments. The CD-1 mouse strain with a higher body weight 
was therefore more appropriate for experiments with JZL 184. 
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 Schlosburg et al. (2010) This thesis 
Mouse strain C57BL/6J CD-1 
JZL 184 dose  
i.p., once daily 
40 mg/kg, 
vehicle 
4 mg/kg, 
10 mg/kg, 
40 mg/kg, 
vehicle 
JZL 184 treatment 
period 
1 day (acute) or  
6 days (chronic) 
1 day (acute), 
3 days (subacute) or 
14 days (chronic) 
Decapitation 2 h after last treatment 24 h after last treatment 
Experimental  
methods 
Endocannabinoid levels  
using LC-MS/MS 
CB1 receptor function  
using 35S-GTPγS binding 
and further in vivo and in vitro methods 
Endocannabinoid levels  
using LC-MS/MS 
CB1 receptor function  
using 35S-GTPγS binding 
 
Tissue used in 
experiments 
Whole brain 
Hippocampus hemispheres 
- right one in LC-MS/MS 
- left one in binding 
Table 21. Procedural differences in the experimental models used by Schlosburg et al. (2010) and in this thesis. 
 
2.1 Endocannabinoids determined by LC-MRM 
As expected, the 2-AG, but not AEA concentration in mouse hippocampus increased with 
increasing JZL 184 treatment duration and with increasing JZL 184 dose (see Figure 20A and B). 
Moreover, the concentration of AA decreased with increasing JZL 184 dose. This alteration could 
be expected as well since AA is formed by the enzymatic reaction involved in 2-AG degradation 
(see section A.2.1.2, Figure 6). 
Unlike in the study of Schlosburg et al. (2010) in which also a modest increase in AEA, the other 
major endocannabinoid, was shown after chronic JZL 184 treatment, even the highest JZL 184 
dose (40 mg/kg) did not affect AEA in our experiments (Figure 20B). This discrepancy could be 
due to the time point of the measurement (2 h after injection in the study of Schlosburg et al. 
(2010) and 24 h after injection in this thesis). Indeed, the supplementary data of Schlosburg et 
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al. (2010) showed that 26 h after the final JZL 184 injection, the AEA level was no longer altered 
whereas the 2-AG level was still enhanced. Like in the study of Schlosburg et al. (2010), chronic 
treatment with 40 mg/kg JZL 184 elevated 2-AG concentration and decreased AA level in this 
thesis. The analysis of additional doses of JZL 184 and of various treatment periods showed that 
the lowest JZL 184 concentration, which effectively increased the 2-AG level, was  
10 mg/kg (Figure 20A). After 3 days, an increasing trend after 10 mg/kg and a significant 
increase after 40 mg/kg JZL 184 occurred. JZL 184 at 4 mg/kg failed to affect the 2-AG level, 
irrespective of the duration of the treatment. However, surprisingly, the AA concentration was 
significantly decreased after chronic treatment with 4 mg/kg and not 10 mg/kg of JZL 184 
(Figure 20C). 
To sum up, in the LC-MRM experiments, the JZL 184 dose of 40 mg/kg effectively increased 2-AG 
at each time period, whereas 10 mg/kg of JZL 184 showed an increasing tendency in 2-AG level, 
which became significant only after 14 days. 
 
2.2 CB1 receptor activity determined by 35S-GTPS binding 
Basal 35S-GTPγS binding, which was decreased by repeated administration of 9-THC (see C.1.2), 
remained unaffected after the increase in the endogenous level of 2-AG by JZL 184, irrespective 
of its dose and the treatment duration. This result is surprising since 2-AG is a full and  
9-THC a partial CB1 receptor agonist (Pertwee et al. 2010). On the other hand, the data fit  
to the CP 55,940-induced facilitation of 35S-GTPγS binding. Thus, no significant effects in  
35S-GTPγS receptor binding were observed here and the concentration-response curves of all 
treatments and doses did not differ significantly (curves for animals treated for 14 days are 
shown in Figure 21). The strongest treatment schedule, i.e., 40 mg/kg JZL 184 for 14 days, 
showed a decreasing trend in the ‘cmp over basal’ range of the concentration-response curve, 
compared to the lower JZL 184 doses and the vehicle treated control. 
Schlosburg et al. (2010), who had treated mice with 40 mg/kg of JZL 184 for  
6 days (Table 21), postulated a desensitization of the CB1 receptor, although most of the  
35S-GTPγS receptor binding concentration-response curves only tended to be lower than the 
curves related to the vehicle-treated animals. However, comparison of the Emax (maximal 
effect) of the curves indeed showed a significant decrease of the binding after JZL 184 treatment. 
The autoradiography analysis confirmed this information. The lack of a significant effect in the 
present work in comparison with the 35S-GTPγS receptor binding results on whole brain 
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homogenates published by Schlosburg et al. (2010) is surprising, especially due to the extremely 
high expression of the CB1 receptor in the hippocampus. 
In this context, two comments about the handling of the 35S-GTPγS receptor binding data by 
Schlosburg et al. (2010) are necessary. In the work of Schlosburg et al. (2010) 35S-GTPγS 
receptor binding was expressed as % stimulation of basal and not in absolute terms. If data are 
handled in such a manner, important information may be obscured. Second, they studied 
binding curves not only in JZL 184 (and vehicle) treated mice but also in mice chronically treated 
with the FAAH inhibitor PF3845 or its vehicle and in MAGL deficient mice (MAGL-/-) compared 
to their wild type (MAGL+/+) controls. Surprisingly, the maximal binding effect of the two vehicle 
treated controls and MAGL+/+ mice showed different values of the % stimulation. The maximal 
effect was about 75 %, about 120 % and more than 150 %, respectively. Because of the large 
discrepancy between the three control groups, comparison of the three treatment schedules 
within the study of Schlosburg et al. (2010) and comparison between their and our results is 
questionable. 
In summary, the CP 55,940-induced increase in 35S-GTPγS binding upon repeated administration 
of 40 mg/kg JZL 184 underwent tolerance in the study by Schlosburg et al. (2010) but only 
tended to do so in the present one. Nonetheless, there is a common denominator of both studies, 
i.e., one can assume that the increased concentration of 2-AG is more or less cancelled out by a 
down-regulation of CB1 receptor function or, in other words, this treatment schedule will not 
allow a long-term treatment e.g. of age-related cognitive deficits. 
While our experiments were in progress, two papers appeared in which doses of JZL 184  
lower than 40 mg/kg were examined. In the study of Kinsey et al. (2013) behavioural 
parameters (antinociceptive and gastroprotective effect), parameters of the CB1 receptor 
function in vitro and the 2-AG level were considered (see Table 22 for a comparison of  
the methods used in the study of Kinsey et al. (2013) and for present thesis). Repeated 
administration of doses  16 mg/kg led to tolerance to the antinociceptive effects of JZL 184  
and cross-tolerance to the effect of 9-THC in vivo and to a decrease in density (determined  
by 3H-SR141716A binding) and function of CB1 receptors (determined by 35S-GTPγS). On the 
other hand, JZL 184 doses  8 mg/kg retained their antinociceptive and gastroprotective effects 
after chronic MAGL blockade, without CB1 receptor adaptation. Our finding that JZL 184 at a 
dose of 10 mg/kg enhances 2-AG and has no effect on 35S-GTPγS receptor binding agrees with 
the results of Kinsey et al. (2013). On the other hand, although the MAGL inhibitor in our project 
was applied for 14 days (and not for 6 days as by Kinsey et al. 2013), the 35S-GTPγS receptor 
binding concentration-response curves and maximal binding effects did not differ significantly 
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after JZL 184 at 40 mg/kg. Kinsey et al. (2013) stated that doses of JZL 184  8 mg/kg caused 
beneficial effects whereas doses of  16 mg/kg caused tolerance-dependent effects. Unlike in 
this thesis, JZL 184 at 4 mg/kg significantly increased 2-AG levels in the study of Kinsey et al. 
(2013). This discrepancy may be due to the different time-point of mouse decapitation (2 h after 
the last injection by Kinsey et al. (2013) and 24 h after the last JZL 184 injection in this thesis).  
In this thesis JZL 184 at 10 mg/kg was considered to be the lowest effective dose causing 2-AG 
elevation without affecting CB1 receptor function, even after 14 days of JZL 184 administration. 
In the second study (Ghosh et al. 2013), behavioural experiments were performed only. JZL 184 
reduces nociception in the carrageenan model of the mouse through a cannabinoid receptor 
mediated mechanism; the analgesic effect of JZL 184 undergoes tolerance after repetitive 
treatment with high doses (16 or 40 mg/kg) but not after a low dose (4 mg/kg). This data 
supports our findings that 10 mg/kg did not yet lead to tolerance development of 35S-GTPγS 
binding. 
To sum up, 10 mg/kg is an appropriate dose of JZL 184 which elevates 2-AG concentration 
without CB1 receptor desensitisation after repetitive treatment (14 days). The doses between  
10 mg/kg and 40 mg/kg should be further investigated to determine the highest possible dose of 
JZL 184 which increases 2-AG but does not affect CB1 receptor function. 
 Kinsey et al. (2013) This thesis 
Mouse strain C57BL/6J CD-1 
JZL 184 treatment period 6 days 14 days  
Decapitation 2 h after last injection 24 h after last injection 
Experimental methods 
Behavioural tests 
Endocannabinoid levels  
using LC-MS/MS 
35S-GTPγS receptor binding 
[3H]SR141716A binding 
 
Endocannabinoid levels  
using LC-MS/MS 
35S-GTPγS receptor binding 
JZL 184 doses and 
alterations of  
35S-GTPγS receptor 
binding 
 8 mg/kg – no receptor 
alterations 
 16 mg/kg – significant 
decrease in receptor binding 
(no data for > 8 - 16 mg/kg) 
4 mg/kg – no receptor alteration 
10 mg/kg – no receptor 
alteration 
40 mg/kg – tendency towards a 
decrease in receptor binding 
Table 22. Differences in the experimental models used by Kinsey et al. (2013) and in this thesis.   
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3. Searching for H4  receptors 
3.1 Searching for mRNA expression: RT-PCR 
H4 receptors are primarily distributed in immune cells, e.g., mast cells, lymphocytes, eosinophils, 
NK cells (as reviewed by Tiligada et al. 2009). It is, however, also of interest to study whether 
they may occur in the brain. Although Liu et al. (2001) failed to detect histamine H4 receptor 
mRNA in the brain of guinea pig and mouse, this thesis shows that H4 receptor mRNA is 
detectable in the cerebral cortex of the guinea pig. Identification of H4 receptor transcripts in the 
mouse cortex was shown before by our group (Schulte 2011). Although the findings made with 
the PCR method may seem meaningful, they must be discussed critically. Thus, H4 receptor 
mRNA detection using the PCR method does not prove in which specific cell type the H4 receptor 
occurs and the PCR signal may originate from immune cells in the brain. Other authors tried to 
detect the H4 receptor on the protein level; Connelly et al. (2009) and Lethbridge and Chazot 
(2009) provided immunological evidence (immunoblotting) for the presence of H4 receptors in 
the human and mouse brain. Nevertheless, also these results must be assessed critically since 
the H4 receptor antibodies used in those studies did not fulfil the stringent criteria for antibodies 
against G protein-coupled receptors (Michel et al. 2009; Beermann et al. 2012; Seifert et al. 
2013). 
 
3.2 Searching for a functional readout: 35S- GTPS binding 
Considering the PCR findings which pointed to the H4 receptor presence in the brain and the 
problems encountered with H4 receptor antibodies, we searched for H4 receptors in the cerebral 
cortex of guinea pig and mouse in a functional model. For this purpose 35S-GTPγS experiments 
with application of various histamine H4 ligands (for chemical structures see Table 4) were 
performed. For the sake of comparison, H3 receptor ligands were studied as well. The H3 
receptor ligands R-α-methylhistamine and thioperamide and the H4 receptor ligands  
4-methylhistamine, JNJ-7777120 and ST-1006 were investigated under the same experimental 
conditions on cortical membranes of two animal species, guinea pig and mouse. The 35S-GTPS 
binding assay was chosen since it allows the detection of many types of functional Gi/o protein-
coupled receptors (Strange 2010). 
The H4 receptor agonist, 4-methylhistamine (Lim et al. 2005), failed to enhance 35S-GTPS 
binding on cortical membranes from the mouse (up to 30 µM). By contrast, in guinea pig cortex, 
concentrations of 10 and 100 µM increased the specific 35S-GTPS binding. The activation of  
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35S-GTPS binding, however, occurred at concentrations markedly exceeding the Ki value of  
50 nM of 4-methylhistamine at H4 receptors (Lim et al. 2010). In order to provide further 
evidence, additional H4 receptor ligands were studied. The H4 receptor antagonist JNJ-7777120 
(Jablonowski et al. 2003) at 1 µM (corresponding to its Ki value; Lim et al. 2010) failed to 
influence the 35S-GTPS binding, regardless of whether it was added to 4-methylhistamine or 
given alone. Moreover, the partial H4 receptor agonist, ST-1006 (Sander et al. 2009), also failed 
to affect the 35S-GTPS specific binding in guinea pig cortex membranes even at 100 µM which is 
more than thousandfold higher than its Ki at human H4 receptors. In conclusion, our data suggest 
that H4 receptor activation does not lead to an increase in 35S-GTPS binding on guinea pig and 
mouse cortical membranes. 
To confirm that proper experimental conditions were used in 35S-GTPγS binding experiments 
with H4 the receptor ligands, 35S-GTPγS binding experiments with H3 receptor ligands were 
conducted as positive control on cerebral cortex membranes from guinea pig and mouse. The H3 
receptor agonist, R-α-methylhistamine (Arrang et al. 1987), activated 35S-GTPγS binding both in 
mouse and guinea pig cerebral cortex membranes. The binding experiments on mouse cerebral 
cortex membranes confirm the data previously published by our group (Nickel et al. 2001). 
Activation of 35S-GTPγS binding by R-α-methylhistamine on guinea pig cortex is shown here for 
the first time. The addition of the H3 receptor antagonist thioperamide (Arrang et al. 1987) 
caused a rightward shift of the concentration-response curve of R-α-methylhistamine, as 
expected. The potencies of R-α-methylhistamine and thioperamide (Table 19) are shown again 
in Table 23 together with values obtained in other functional H3 receptor models of the same 
species. 
 
Ligand 
Potency 
estimate 
Experimental model 
Guinea 
pig 
Mouse 
NMRI C57BL/6J 
RαMH 
pEC50  35S-GTPγS binding activation 8.31 7.82 8.41 
pEC50 Inhibition of noradrenaline release 7.83 7.54 ND 
Thio-
peramide 
pA2 35S-GTPγS binding activation 8.21 ND 8.51 
pA2 Inhibition of noradrenaline release 7.83 8.74 ND 
Table 23. Potencies of the H3 receptor agonist R-α-methylhistamine (RαMH) and the H3 receptor antagonist 
thioperamide for the activation of 35S-GTPγS binding and the inhibition of noradrenaline release in guinea pig and 
mouse. Comparison of this study and the literature. C57BL/6J, NMRI – mouse strains; ND – not determined.  
1 Figure 23B; 2 Nickel et al. (2001); 3 Timm et al. (1998); 4 Schlicker et al. (1992). 
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Considering the possibility that the H4 like the H3 receptor may serve as a presynaptic receptor 
leading to the inhibition of exocytotic noradrenaline release (Schlicker et al. 1994) superfusion 
experiments were performed on human, guinea pig and mouse cortex slices and the electrically 
induced 3H-noradrenaline release was measured. In these experiments (data not shown), 
noradrenaline release was not affected by 4-methylhistamine although H3 receptor-mediated 
inhibition of noradrenaline release occurred. The latter data are an additional argument that H4 
receptor do not occur in the brain. 
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E. Summary (Abstract) 
This thesis focuses on two Gi/o protein-coupled receptors, namely the cannabinoid CB1 and the 
histamine H4 receptor. In the first and second part of the study, the plasticity of CB1 receptors in 
terms of age and of pre-treatment with an exogenous and endogenous cannabinoid was 
examined. In the third part, I searched for the occurrence of H4 receptor mRNA and of functional 
H4 receptors in the brain. 
In the first project, CB1 receptor plasticity was studied in the Open Field Test and in a 
biochemical paradigm (G protein activation quantified by the 35S-GTPγS binding method) of 
adolescent (6-8 week-old) and aged (12-month-old) mice. Single administration of the 
exogenous cannabinoid Δ9-tetrahydrocannabinol (Δ9-THC) decreased the distance travelled and 
the rearing number and increased the resting time to about the same extent in adolescent and 
old animals. Pre-treatment of mice with Δ9-THC (7 injections over a time period of 3.5 days) 
attenuated the effect of a challenge dose of Δ9-THC by about 50 % in the rearing and resting time 
paradigm, independent of the age; with respect to the distance travelled, the attenuation of the 
effect tended to be slightly less pronounced in old when compared to adolescent mice. Basal 35S-
GTPγS binding was less pronounced in hippocampal membranes from aged when compared to 
adolescent mice. Δ9-THC pre-treatment attenuated basal binding by about 50 % in membranes 
from adolescent but had no effect in membranes from old mice. The increase in 35S-GTPγS 
binding elicited by the cannabinoid receptor agonist CP 55,940 was less marked in untreated old 
than in untreated adolescent mice. After pre-treatment with Δ9-THC, the CP 55,940-related 
increase in 35S-GTPγS binding was not affected in old but was reduced by about 50 % in 
adolescent mice. The results show that aging markedly affects basal and CP 55,940-induced  
35S-GTPγS binding and the tolerance development of both parameters to Δ9-THC pre-treatment; 
in the behavioural paradigm, aging does not consistently influence tolerance development. 
The second project was dedicated to the effect of an endogenous cannabinoid, i.e.,  
2-arachidonoyl glycerol (2-AG), on basal and CP 55,940-induced 35S-GTPγS binding; formation of 
endogenous 2-AG was increased by blockade of its degrading enzyme by  
JZL 184. The question was whether a treatment schedule can be found under which  
2-AG (determined by liquid chromatography tandem mass spectrometry) is increased but 
adaptive down-regulation of CP 55,940-induced 35S-GTPγS binding is avoided. Adolescent mice 
were pre-treated with JZL 184 at 4, 10 or 40 mg/kg over a period of 14 days. JZL 184 at 4 mg/kg 
did not affect hippocampal 2-AG levels and the CP 55,940-induced 35S-GTPγS binding in 
hippocampal membranes. The next higher dose (10 mg/kg) increased 2-AG without affecting  
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CP 55,940-induced 35S-GTPγS binding. The highest dose (40 mg/kg) increased 2-AG but 
simultaneously also decreased the CP 55,940-induced 35S-GTPγS binding. Basal 35S-GTPγS 
binding was not affected by JZL 184 at 4 - 40 mg/kg. The data suggest that 10 mg/kg of JZL 184 
when administered over a longer time period leads to a sustained increase in 2-AG. Since this 
dose does not cancel out the activation of CB1 receptors by their simultaneous down-regulation, 
administration of JZL 184 10 mg/kg may be a strategy of long-term cannabinoid treatment. 
The occurrence and role of the histamine H4 as opposed to the CB1 receptor in the brain is 
unclear. In the third project, I could show that H4 receptor mRNA is detectable in the cerebral 
cortex of mice and guinea pigs, using the reverse transcriptase polymerase chain reaction. The 
search for a functional correlate was, however, negative; thus, I could not show a H4 receptor-
related facilitation of 35S-GTPγS binding in cortical membranes of either species. As a positive 
control, histamine H3 receptor activation did increase 35S-GTPγS binding. 
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